

Supplementary Material

eMethods1. Search strategy

eMethods2. Data extraction form

eMethods3. Power analysis

eTable1. Detailed characteristics of included meta-analyses

eTable2. Detailed reporting of study funding source, author-industry financial ties, and author-industry employment from included RCTs

eMethods1. Search strategy

To obtain our sample, we searched the MEDLINE database via PubMed on October 19, 2018 using the following search strategy:

```
((("Randomized Controlled Trials as Topic"[Mesh] or randomized control trial [tiab] or randomized controled trial [tiab] OR randomized controlled trial [tiab] or randomized control trials [tiab] OR randomized controled trials [tiab] OR Randomized controlled trials [tiab] or randomised control trial [tiab] or randomised controled trial [tiab] OR randomised controlled trial [tiab] or randomised control trials [tiab] OR randomised controled trials [tiab] OR Randomised controlled trials [tiab]) AND ("Therapeutic Uses"[Mesh] OR "Vaccines"[Mesh]) AND ("Meta-Analysis" [Publication Type] or meta analysis [tiab]) AND (systematic review [tiab] OR search [tiab] or searched [tiab] or MEDLINE [tiab] OR PubMed [tiab])))
```

eMethods 2. Data extraction form

First Author, last name: Last name of first author of meta-analysis

Year of publication (or in press): Year of publication of meta-analysis

Journal: Name of journal in which meta-analysis was published

Journal Impact factor: Where meta-analysis published (low-high split or continuous based on data distribution)

Specialty area of Journal: Where meta-analysis published (per Thomson Reuters Journal Science Citation Index - Expanded categories)

Cochrane Review (Y/N): Is the meta-analysis a Cochrane Review? Select "Yes" even if the Cochrane Review is being published in another journal

Response from radio options:

- Y (Yes)
- N (No)

Journal policies for reporting COI of Included Trials: Presence or absence of instructions for reporting in the author instructions

- Y (Yes)
- N (No)

of RCTs synthesized in Meta-Analysis (total RCTs in included meta-analysis related to drugs)

Date Range of Included Trials: Date range in years of publication of studies (RCTs) included related to drugs in the meta-analysis (XXXX - XXXX). Use "In press" for end date if there are in press trials. Use "Unpublished" if a trial is in progress or has never been published.

Study population: Characteristics of study population of included trials (e.g. condition/disorder, adult/child)

Pharmacological agent: Pharmacologic treatment evaluated in the meta-analysis

- Name(s) of treatment if specific drug(s) investigated
- Class of treatment if broader category of drugs investigated, and number of drugs evaluated (e.g. SSRIs – 5 included)

Control/comparison arms: Other treatment arms (control/comparison) included in the meta-analysis (e.g. placebo, name of comparison pharmacologic treatment, name of behavioral intervention)

Meta-Analysis Author Financial Ties / Funding Sources Reported: Does the meta-analysis report meta-analysis author financial ties (including former and current industry employment) and/or the funding source? Note that reporting "no funding" is different from not reporting.

Response from radio options:

- Meta-analysis author financial ties
- Meta-analysis funding sources
- Both financial ties and funding sources
- Neither reported

Funding Source of Meta-Analysis (if applicable – only shown if above item indicates meta-analysis funding sources reported or both financial ties and meta-analysis funding sources reported) Source of financial support for the meta-analysis:

Response from radio options:

- Industry
- Combined industry and non-industry

- Non-industry (e.g. public granting agency, private not-for-profit granting agency)
- No study funding

Type of Industry Funding (if applicable – only shown if above item indicates industry funding or combined industry and non-industry present): If the meta-analysis is industry funded, what is the type of support provided by industry? Response from radio options:

- Financial support
- Resources (e.g. statistical analyses)
- Both financial support and resources

of Meta-Analysis Authors: Number of authors of the meta-analysis (count authors named in byline or in an author group)

of Meta-Analysis Authors with Financial Ties to Industry (if applicable – only shown if meta-analysis author financial ties or both financial ties and meta-analysis funding sources are reported): Number of authors of the meta-analysis who have financial ties such as industry board member, consultant, investments, patents, research funding, royalties (including former, and excluding current industry employment):

- Numbers 0 - ≥ 10

Meta-Analysis Authors with Current Industry Employment (if applicable – only shown if meta-analysis author financial ties or both financial ties and meta-analysis funding sources are reported): Number of authors of the meta-analysis who are current industry employees.

Response from radio options:

Numbers 0 - ≥ 10

Quality or Risk Assessment of Included RCTs (Y/N): Was quality or risk assessment of included RCTs, by methods from Cochrane, Jadad, etc., reported in the meta-analysis.

Response from radio options:

- Y (Yes)
- N (No)

Quality or Risk Assessment Method of Included RCTs (if applicable – only shown if answer to previous item is yes- quality or risk assessment of included RCTs is reported): If the meta-analysis authors report a quality or risk assessment method of included RCTs, what is the reported method of quality assessment?

Meta-analysis Authors Report Funding Sources of Included Studies: Response from radio options:

- Reported for each included study
- Reported in summary statement or for some, but not all, trials
- Included study funding sources not reported

Placement in publication of Included RCTs' Funding Source (if applicable – only shown if the response to Meta-analysis Authors Report Funding Sources of Included Studies is (1) Reported for Each included Study or (2) Reported in summary statement or for some, but not all, trials):

- Abstract
- Main text, other than risk of bias or quality section
- In risk of bias or quality assessment
- Other in main document (e.g., a characteristics of studies table, other table, in a footnote of a table)
- Online appendix
- Lay Summary

Placement in risk of bias or quality assessment of Included RCTs' Funding Source (if applicable – only shown if placement in publication of included RCT's Funding Source is risk of bias or quality assessment):

- Text
- Figure/table
- Both text and figure/table

Meta-analysis Authors Report Author Financial Ties of Included Studies: Response from radio options:

- Reported for each included study
- Reported in summary statement or for some, but not all, trials
- Included study author financial ties not reported

Placement in publication of Included RCTs' Author Financial Ties (if applicable – only shown if the response Meta-analysis Authors Report Author Financial Ties of Included Studies is (1) Reported for Each included Study or (2) Reported in summary statement or for some, but not all, trials):

- Abstract
- Main text, other than risk of bias or quality section
- In risk of bias or quality assessment
- Other in main document (e.g., a characteristics of studies table, other table, in a footnote of a table
- Online appendix
- Lay Summary

Placement in risk of bias or quality assessment of Included RCTs' Author Financial Ties (if applicable – only shown if placement in publication of included RCT's Author Financial ties is risk of bias or quality assessment):

- Text
- Figure/table
- Both text and figure/table

Meta-analysis Authors Report Author Industry Employment of Included Studies: Do the authors of the meta-analysis report current author industry affiliation (employment) for the included studies? Response from radio options:

- Reported for each included study
- Reported in summary statement or for some, but not all, trials
- Included study author industry employment not reported

Placement in publication of Included RCTs' Author Industry Employment (if applicable – only shown if the response to Meta-analysis Authors Report Author Industry Affiliation (Employment) of Included Studies is (1) Reported for Each included Study or (2) Reported in summary statement or for some, but not all, trials):

- Abstract
- Main text, other than risk of bias or quality section
- In risk of bias or quality assessment
- Other in main document (e.g., a characteristics of studies table, other table, in a footnote of a table)
- Online appendix
- Lay Summary

Placement in risk of bias or quality assessment of Included RCTs' Author Industry Employment (only shown if placement in publication of included RCT's Author Industry Affiliation is risk of bias or quality assessment):

- Text
- Figure/table
- Both text and figure/table

Do the authors report a PROSPERO registration number in the text?

- Yes
- No

What is the registration number (e.g., CRD42017062454)? (if applicable – only shown if the response to Do the authors report a PROSPERO registration number in the text? Is yes)

What stages were completed (ignore started) at the time of registration. Make sure to select the earliest registration version at the bottom of the page. Please check all stages that were completed. (if applicable – only shown if the response to Do the authors report a PROSPERO registration number in the text? Is yes)

- Preliminary searches

- Piloting of the study selection process
- Formal screening of search results against eligibility criteria
- Data extraction
- Risk of bias (quality) assessment
- Data analysis
- None completed

Was a registration found in PROSPERO? (if applicable – only shown if the response to Do the authors report a PROSPERO registration number in the text? Is no)

What is the registration number (e.g., CRD42017062454)? (if applicable – only shown if the response to Was a registration found in PROSPERO? Is yes)

What stages were completed (ignore started) at the time of registration. Make sure to select the earliest registration version at the bottom of the page. Please check all stages that were completed. (if applicable – only shown if the response to Was a registration found in PROSPERO? Is yes)

- Preliminary searches
- Piloting of the study selection process
- Formal screening of search results against eligibility criteria
- Data extraction
- Risk of bias (quality) assessment
- Data analysis
- None completed

eMethods3. Power analysis**Allocation ratio: 50% and 50% (1:1)**

20% difference						
Proportion reporting COI		Sample size group 1	Sample size group 2	Sample size total	Actual power	Actual alpha
Low impact	High impact					
10%	30%	69	69	138	.807	.033
20%	40%	90	90	180	.802	.037
30%	50%	102	102	204	.806	.042
40%	60%	102	102	204	.801	.038
50%	70%	102	102	204	.806	.036
60%	80%	90	90	180	.802	.032
70%	90%	69	69	138	.807	.025

Allocation ratio: 30% and 70% (3:7)

20% difference						
Proportion reporting COI		Sample size group 1	Sample size group 2	Sample size total	Actual power	Actual alpha
Low impact	High impact					
10%	30%	105	44	149	.815	.038
20%	40%	141	59	200	.807	.040
30%	50%	165	69	234	.801	.045
40%	60%	168	71	239	.805	.043
50%	70%	166	70	236	.864	.042
60%	80%	148	62	210	.802	.040
70%	90%	133	47	160	.802	.035

eTable1. Detailed characteristics of included meta-analyses**eTable1.** Detailed characteristics of included meta-analyses

First Author	Year	Journal	2017 Impact Factor	Specialty Area	Meta-analysis Funding source(s)	Number of Meta-analysis Authors with Industry Financial Ties / Number of Meta-analysis Authors ^a	Number of drug RCTs Included	Publication Dates of included drug RCTs	Population	Drug Intervention(s)	Comparison Arm(s)
Cochrane Reviews (n = 107)											
Abdel-Rahman ¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	7	2004-2016	Adults (19 years and over) with advanced biliary tract carcinomas	Gemcitabine, vandetanib, S-1 (tegafur + gimeracil + oteracil), gemcitabine + oxaliplatin, 5-fluorouracil + folinic acid, capecitabine	Best supportive care, 5-fluorouracil + cisplatin + radiotherapy
Adams ²	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	36	1994-2012	Participants with or without evidence of cardiovascular disease	Fluvastatin	Placebo
Agabio ³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	27	1969-2015	People with co-occurring depression and alcohol dependence	Antidepressants - 16 types, diazepam, memantine	Placebo, psychotherapy
Al-Shahi Salman ⁴	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Not reported	0/5	11 ^b	1999-2015	Adults (16 years and over) with acute spontaneous intracerebral haemorrhage	Blood clotting factors, antifibrinolytic drugs	Placebo, open control, fresh frozen plasma
Alabed ⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	11	1976-2008	Patients with antipsychotic-induced tardive dyskinesia (TD)	Gamma-aminobutyric acid agonists - 6 types	Placebo
Allegretti ⁶	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	3/8	8	1998-2016	Patients with hepatorenal syndrome	Terlipressin, terlipressin + albumin	Placebo, no intervention, albumin
Arechabala ⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/7	37	1998-2017	Patients undergoing haemodialysis using a central venous catheter	Antibiotic antimicrobial lock solutions - 11 types, non-antibiotic antimicrobial lock	Heparin, saline

Baandrup ⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	1/6	33 ^c	1981-2016	Adult (18 years and over) chronic benzodiazepine users Individuals with antiphospholipid antibodies and no history of thrombosis	solutions - 10 types, antibiotic + non-antibiotic antimicrobial lock solutions - 3 types Valproate, carbamazepine, lithium, pregabalin, captopriam, paroxetine, tricyclic antidepressants - 4 types, alpidem, buspirone, flumazenil, propranolol, progesterone, magnesium aspartate, bromazepam, cyamemazine, zopiclone, flunitrazepam	Placebo, no intervention
Bala ⁹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	3/6	9	1997-2016	Heterosexual adult couples (18 years or more) with a partner having a clinical diagnosis of depressive disorder	Aspirin + anticoagulants, aspirin, aspirin + low molecular weight heparin	Placebo, immunoglobulin, unfractionated heparin
Barbato ¹⁰	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	4 ^d	2000-2012	Psychiatric patients with antipsychotic-induced tardive dyskinesia	Antidepressants - 9 types	Couples therapy
Bergman ¹¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	4	1981-1997		Benzodiazepines - 3 types Tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), norepinephrine reuptake inhibitors (NRIs), nefazodone, ritanserin	Placebo, usual care
Bighelli ¹²	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	2/9	41	1989-2011	Adults (18 years and over) with panic disorder		Placebo
Birks ¹³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/2	30	1996-2017	People with Alzheimer's disease	Donepezil	Placebo
Boyapati ¹⁴	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	3/8	6	1978-2017	Adults (18 years and over) with quiescent Crohn's disease	Azathioprine, infliximab	No treatment, usual care (azathioprine + infliximab)

Brown ¹⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	5	1993-2017	Women of reproductive age with endometriosis	Combined oral contraceptive pill - 3 types	Placebo, leuprolide, goserelin
Bruins Slot ¹⁶	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/2 ^e	13	2008-2014	Adults with atrial fibrillation People with schizophrenia and schizophrenia-like disorders such as schizophreniform disorder, delusional disorder, or schizoaffective disorder	Factor Xa inhibitors - 7 types	Warfarin
Bryan ¹⁷	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	0/3	20	1968-2007	Women of reproductive age with heavy menstrual bleeding	Zuclopenthixol dihydrochloride Antifibrinolytic agents - 2 types, non-steroidal anti-inflammatory drugs (NSAIDs), progestogens, ethamsylate	Placebo, other drugs - 11 types
Bryant-Smith ¹⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	1/4	13	1970-2016	Adults (17 years and over) in non-ICU acute care settings diagnosed with delirium	Antipsychotics - 5 types	Placebo, herbal medicines, levonorgestrel intrauterine system
Burry ¹⁹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/9	9	1996-2016	Adult patients (18 years and older) with ureteral stone disease	Alpha-blockers - 6 types	Nonantipsychotics, placebo
Campschroer ²⁰	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	67	2002-2017	Adults with cancer and adults receiving palliative care with opioid-induced bowel dysfunction	Mu-opioid antagonists - 3 types	Placebo, usual care
Candy ²¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/5	8	1996-2017	Patients with paracetamol (acetaminophen) overdose	Methionine, cysteamine, dimercaprol, acetylcysteine	Placebo, no treatment
Chiew ²²	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	9 ^f	1976-2014	Children aged up to five years with a clinical diagnosis of community-acquired pneumonia (CAP)	Vitamin D	Placebo, antibiotics alone
Das ²³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Not reported	0/3	7	2010-2017	Healthy individuals (16 to 65 years) and pregnant women and their newborns	Inactivated parenteral influenza vaccine	Placebo, no treatment

Demicheli ²⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/7	8	1969-2004	Elderly participants (65 years and over)	Influenza vaccines Fondaparinux, rivaroxaban, low molecular weight heparin, non-steroidal anti-inflammatory drugs, vasotonin, sulodexide,	Placebo
Di Nisio ²⁶	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	2/3	32	1970-2017	Patients with superficial thrombophlebitis of the leg or diagnosis of a thrombus in a superficial vein	heparansulphate, vitamin K antagonists, enzyme therapy, unfractionated heparin, heparin calcium, defibrotide	Placebo, elastic stockings
El-Sayeh ²⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	10	1973-2010	Patients with antipsychotic-induced tardive dyskinesia	Noradrenergic drugs - 2 types, dopaminergic drugs - 7 types	Placebo
Engelen ²⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/5	3	1989-2015	People of all ages on continuous vitamin K antagonist (VKA) or direct oral anticoagulant (DOAC) treatment undergoing an oral or dental procedure	Antifibrinolytic agents - 2 types Selective serotonin reuptake inhibitors (SSRIs) - 4 types, tricyclic antidepressants (TCAs) - 2 types	Usual care (surgical treatment), usual care (surgical treatment) + placebo
Eshun-Wilson ²⁹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/6	10	1994-2014	Adults (18 years and over) living with HIV and depression	People with antipsychotic-induced tardive dyskinesia	Placebo, mirtazapine
Essali ³⁰	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	3	1992-1997	Adults (18 years and over) with insomnia	Calcium channel blockers - 3 types Selective serotonin reuptake inhibitors - 4 types; tricyclic antidepressants - 3 types; other antidepressants - 6 types	Placebo
Everitt ³¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	3/8	23	1978-2013	Regular tobacco smokers (20 years and under)	Nicotine replacement therapy, bupropion	Placebo, insomnia medication - 2 types
Fanshawe ³²	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	4	2004-2014	Subfertile women of reproductive age with polycystic ovary syndrome	Letrozole	Placebo Placebo, selective estrogen receptor modulators, clomiphene citrate
Franik ³³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/5	42	2004-2017			

González ³⁴	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	6	1994-2014	Pregnant women living in malaria-endemic areas	Mefloquine	followed by intrauterine insemination, laparoscopic ovarian drilling, follicle-stimulating hormone, anastrozole
Grabosch ³⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	3	2006-2017	Adult women with moderate or severe cervical intraepithelial neoplasia (CIN)	Non-steroidal anti-inflammatory agents (NSAIDs) - 2 types	Sulfadoxine-pyrimethamine, cotrimoxazole, placebo
Graves ³⁶	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	24 ^h	1981-2017	Adults and children being treated for falciparum malaria	Primaquine	Usual treatment, bulaquine
Haas ³⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	11	1997-2017	Pregnant women who were about to receive a cesarean delivery	Antiseptic solutions - 3 types	Placebo, no treatment
Hakoum ³⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/10	15	1991-2009	People with cancer and venous thromboembolism	Low molecular weight heparin, unfractionated heparin	Fondaparinux
Heras-Mosteiro ³⁹	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/10	89	1990-2015	Immunocompetent patients with localised Old World cutaneous leishmaniasis	Antimonials – 2 types, non-antimonials – 22 types	Placebo, no treatment, alternative therapies - 7 types, other drug comparators - 6 types, other non-drug comparators - 4 types
Janmaat ⁴⁰	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/8	41	1980-2015	People with esophageal or gastroesophageal junction cancer	Chemotherapy, targeted therapy, EGFR-targeting agents, cetuximab, ramucirumab	Best supportive care, unspecified control
Jefferson ⁴¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/4	41	1971-2016	Healthy children (15 years and under)	Influenza vaccine - 2 types	Placebo, no intervention
Jung ⁴²	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	19	2006- Unpublished	Middle-aged and older men (40 or over) with lower urinary tract symptoms as a result of benign prostatic hyperplasia	Silodosin, tamsulosin, naftopidil, and alfuzosin	Placebo

Kaempfen ⁴³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	3	2013-2017	Preterm infants	Propranolol	Placebo, no treatment
Kahale ⁴⁴	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/10	7	1979-2012	Ambulatory people with cancer	Warfarin, apixaban	Placebo, no treatment
Kahale ⁴⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/10	13	1990-2013	People with cancer and central venous catheters	Anticoagulant - 6 types Vitamin K antagonist - 2 types, direct oral anticoagulant - 4 types;	Placebo, no treatment
Kahale ⁴⁶	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/11	16	2001-2018	People with cancer and venous thromboembolism	low molecular weight heparin - 4 types	Anticoagulants
Kapur ⁴⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	3/5	7	1992-2012	Children and adults with bronchiectasis	Corticosteroids - 3 types	Placebo, no treatment
Kelly ⁴⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	2/8	15	1997-2014	Adults and children with bronchiectasis	Macrolide antibiotics - 4 types	Placebo, no intervention
Knightly ⁴⁹	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/7	25	1996-2017	Adults and children with acute exacerbation of asthma	Magnesium sulfate	β2 -agonist, β2 -agonist + ipratropium, placebo
Kopsaftis ⁵⁰	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	11	1961-2004	People with chronic obstructive pulmonary disease	Inactivated influenza vaccine Aminosalicylates - 4 types, corticosteroids, superoxide dismutase, amifostine, bile acid sequestrants, magnesium oxide, misoprostol, octreotide, selenium, sodium butyrate, sucralfate, ibuprofen, famotidine, smectite, simethicone, tropisetron	Placebo
Lawrie ⁵¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/9	38	1978-2016	Adults (18 years and over) undergoing radiotherapy for pelvic cancers		Placebo, no treatment
Leathersich ⁵²	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	8	1987-2007	Women with signs of fetal distress	Tocolytic agents – 7 types	Usual care, emergency delivery, cessation of oxytocic infusion
Lethaby ⁵³	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/3	38	1989-2012	Women with uterine fibroids	Gonadotropin-hormone releasing analogue,	Placebo, no treatment

López-Briz ⁵⁴	2018	Systematic Reviews Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	11	2002-2015	Adults with central venous catheters	Heparin	selective progesterone-receptor modulators	0.9% sodium chloride (normal saline solution)
Marchant ⁵⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	2/4	3	1993-2012	Children (18 years and under) with prolonged wet cough (longer than 10 days)	Antibiotics - 2 types		Placebo, no treatment
Matar ⁵⁶	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	7	1963-1999	Patients with schizophrenia	Fluphenazine		Placebo
Matar ⁵⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/11	20	1986-2018	People with solid or hematologic cancer undergoing surgery	Low-molecular weight heparin (LMWH) - 10 types		Unfractionated heparin (UFH), fondaparinux
McNicol ⁵⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/3	13	1992-2016	Postoperative paediatric patients (17 years and under) Children (16 years and under) presenting to a hospital or emergency department in an acute tonic-clonic convulsion	Ketorolac		Placebo, opioid
McTague ⁵⁹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	18	1995-2014		Lorazepam		Diazepam + phenytoin, diazepam, paraldehyde, midazolam
Mhaskar ⁶⁰	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	24	1982-2015	Patients with multiple myeloma (MM)	Bisphosphonates - 5 types		Placebo, no treatment - Network meta-analysis
Milligan ⁶¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	18	1980-2016	Adults and children	Typhoid fever vaccines - 4 types		No treatment, placebo, typhoid-inactive agents
Monk ⁶²	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	32	1993-2016	People undergoing orthodontic treatment	Tramadol, non-steroidal anti-inflammatory drugs, paracetamol, local anaesthetic		Placebo, no treatment
Montero ⁶³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding ⁱ	1/7	10	1991-2012	Patients with hepatitis C virus-associated mixed cryoglobulinaemia	Rituximab, interferon, immunosuppressive drug therapy		Usual care, immunoadsorption apheresis
Mücke ⁶⁴	2018	Cochrane Database of	6.8	Medicine, General & Internal	Non-industry	2/5	16	2004-2017	Adults (18 years and over) with chronic neuropathic pain	Cannabis-based medicines - 5 types		Placebo, dihydrocodeine

Narula ⁶⁵	2018	Systematic Reviews Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	3/7	10 ^j	1990-2014	Adults and children with Crohn's disease	Corticosteroids - 5 types	Enteral nutrition
Nevitt ⁶⁶	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/5	76	1981-2015	Adults or children with partial onset seizures or generalised onset tonic-clonic seizures	Antiepileptic drugs - 10 types	Network meta-analysis
Nevitt ⁶⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/4	14	1995-2015	Adults and children with focal onset or generalised onset seizures	Lamotrigine	Carbamazepine
Norman ⁶⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/6	78	1985-2016	Adults (18 years and over) with venous leg ulcers	Topical agents - 10 types	Dressings - 12 types; Network meta-analysis
Normansell ⁶⁹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	6	1974-2016	Children and adults with acute asthma exacerbation	Antibiotics - 4 types Propranolol, timolol maleate, bleomycin, atenolol, prednisolone,	Placebo
Novoa ⁷⁰	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/7	24	1977-2016	Children (17 years and under) with single or multiple haemangiomas located on the skin	captopril, ibuprofen + paracetamol, methylene blue, triamcinolone, methylprednisolone	Placebo, radiation, lasers
Ohlsson ⁷¹	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	0/2	34	1991-2017	Preterm (< 37 weeks' gestation) and low birth weight (< 2500 grams) infants less than eight days of age	Erythropoiesis-stimulating agents (ESAs) - 2 types	Placebo, no treatment
Ostinelli ⁷²	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	1/5	3	2005-2016	Adults exhibiting aggression or agitation (or both) due to psychosis	Aripiprazole	Placebo, other anti-psychotic medications - 2 types
Ostinelli ⁷³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	9	2010-2014	Patients with psychosis-induced aggression or agitation	Risperidone	Haloperidol, olanzapine, quetiapine, oxcarbazepine, valproic acid
Ostuzzi ⁷⁴	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/5	7	1985- Unpublished	Adults (18 years and over) with cancer and depression	Antidepressants - 6 types	Placebo

Parker ⁷⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	2/5	2	2011-2013	Children and adults with active Crohn's disease	Naltrexone	Placebo Tamoxifen, interferon-alpha, interleukin-2, interferon-alpha + interleukin-2, Bacille Calmette-Guérin (BCG), corynebacterium parvum, anti-PD1 monoclonal antibodies, sorafenib, elesclomo, anti-angiogenic drugs
Pasquali ⁷⁶	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/5	122	1972-2015	Patients with unresectable lymph node metastasis and distant metastatic cutaneous melanoma	Single agent chemotherapy, polychemotherapy, temozolomide, dacarbazine, anti-CTLA4 monoclonal antibodies, other immunostimulating agents, MEK inhibitors	
Pike ⁷⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	4	2007-2017	Children (18 years and under) with asthma	Omalizumab, leukotriene receptor antagonists - 2 types, corticosteroids	Placebo
Rirash ⁷⁸	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Not reported	Not reported/8	38	1982-2000	Patients with Raynaud's phenomenon	Calcium channel blockers	Placebo
Robertson ⁷⁹	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	6	1995-2016	Adults (18 years and over) with unprovoked venous thromboembolism	Warfarin, aspirin, rivaroxaban	Placebo
Romero ⁸⁰	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	7	1983-1999	Sexually active adults (16 years and over) with genital ulcers compatible with chancroid	Macrolide antibiotics - 3 types	Other antibiotics - 4 types
Rosomeck ⁸¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	15	1996-2016	People with scabies of all ages and either sex	Ivermectin	Permethrin
Rüschén ⁸²	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	7	1995-2012	Adults (18 years and over) undergoing intraocular surgery	Hyaluronidase Methylphenidate, modafinil, cholinesterase inhibitors (ChEIs), atypical antipsychotics, antidepressants, mibampator, valproate, semagacestat	Local anaesthetic mixture (standard treatment)
Ruthirakuhan ⁸³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	2/5	21	1998-2017	People with Alzheimer's Disease		Placebo

Sankar ⁸⁴	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	0/3	6	2011-2016	Preterm infants with retinopathy	Anti-vascular endothelial growth factor agents - 2 types Levosimendan, dobutamine, enoximone, epinephrine, norepinephrine-dobutamine, amrinone, dopexamine, dopamine, nitric oxid	Cryo/laser therapy
Schumann ⁸⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	3/9	13	1990-2013	Adults (18 years and over) with cardiogenic shock or acute low cardiac output syndrome	Acetazolamide, ibuprofen, dexamethasone, oxygen, nitric oxide, gabapentin, magnesium sulphate, sumatriptan	Placebo, no treatment
Simancas-Racines ⁸⁶	2018	Cochrane Database of Systematic Reviews Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	13 ^k	1992-1994	People suffering from high altitude illness	Salmeterol, tiotropium	Placebo, normal air, unspecified control, paracetamol
Smith ⁸⁷	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/2	4	1998-2015	Adults and children with cystic fibrosis	Intramuscular or intravenous opioids - 16 types Alkaloids - 3 types, antidepressants - 3 types, levetiracetam, cyproheptadin, promethazine, buspiron, cognitive enhancers - 2 types, VMAT2 inhibitors, ethyleicosapentaenoic acid (ethyl-EPA), hormones - 3 types, lithium, ceruletide	No treatment, placebo Placebo, no treatment, intramuscular or intravenous opioids - 16 types
Smith ⁸⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	70	1958-2017	Women in labour	People with chronic psychiatric disorders People with coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease, or at high risk of atherothrombotic disease	Placebo
Soares-Weiser ⁸⁹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/5 ^l	24 ^m	1971-2014	Adults with chronic psychiatric disorders People with coronary disease, ischaemic cerebrovascular disease, peripheral arterial disease, or at high risk of atherothrombotic disease	Clopidrogel Articaine, articaine + epinephrine, lidocaine + epinephrine, bupivacaine + epinephrine, mepivacaine + epinephrine, mepivacaine + levonordefrin,	Placebo, usual care (aspirin)
Squizzato ⁹⁰	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	2/5	15	2001-2017	Individuals undergoing dental procedures and volunteers who took part in simulated scenario studies		Local anaesthetics
St George ⁹¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/7	123	1954-2017			

										mepivacaine, prilocaine, prilocaine + felypressin, prilocaine + epinephrine	
Stern ⁹²	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	17	1972-2015	Adults and children with pneumonia Children and adolescents (18 years or under) with autism spectrum disorder (ASD) or pervasive developmental disorder (PDD)	Corticosteroids - 7 types	Placebo, usual care
Sturman ⁹³	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	0/3	4	1995-2013	Psychiatric patients with antipsychotic-induced tardive dyskinesia	Methylphenidate	Placebo
Tammenmaa-Aho ⁹⁴	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	14	1976-2014	Adults (17 years and over) with severe mental illness and co-occurring substance use disorder	Cholinergic drugs - 6 types	Placebo
Temmingh ⁹⁵	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	2/4	8	2006-2014	Adults with HIV-associated cryptococcal meningitis	Risperidone	Other antipsychotics - 5 types
Tenforde ⁹⁶	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/7	13	1997-2018		Antifungal induction therapies - 6 types	Network meta-analysis H2 receptor antagonists, proton pump inhibitors, prostaglandin analogues, anticholinergics, antacids, sucralfate, teprenone, naloxone, bioflavonoids
Toews ⁹⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/7	103 ^a	1977-2016	People admitted to intensive care units	H2 receptor antagonists, proton pump inhibitors, prostaglandin analogues, anticholinergics, antacids, sucralfate, teprenone, naloxone, bioflavonoids	placebo, no treatment, other medication (not defined)
Venekamp ⁹⁸	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	1/4	3 ^a	1992-1996	Children (16 years and under) with recurrent acute otitis media	Antibiotics - 3 types	Grommets
Vermeij ⁹⁹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	8	1998-2016	Individuals who had an ischemic or hemorrhagic stroke	Preventive antibiotics	Placebo, standard care

Vietto ¹⁰⁰	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	33	1983- Unpublishe d	Patients with critical limb ischaemia unsuitable for rescue or reconstructive intervention	Prostanoids - 7 types	Placebo, other active drugs - 4 types
Wall ¹⁰¹	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/5	5	1995-2014	Patients with acute bacterial meningitis Adult patients (over 18 years) undergoing any elective or urgent surgical procedure under general anaesthesia	Glycerol	Treatment as usual
Weibel ¹⁰²	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	3/10	68	1985-2017	Adult patients with primary hypertension	Lidocaine Thiazides, beta-blockers, angiotensin-converting-enzyme inhibitors, calcium channel blockers	Placebo, no treatment, thoracic epidural analgesia - 3 types
Wright ¹⁰³	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/3	24	1966-2008	Patients with focal epilepsy that failed to respond to one or more antiepileptic drugs		Placebo
Xiao ¹⁰⁴	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/4	2	2001-2003	Adult and elder patients with solid tumours	Losigamone	Placebo
Zhang ¹⁰⁵	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	No funding	0/5	3	2009-2015	Adults (18 years and over) with neuropathic pain	Thrombopoietin receptor agonists (TPO-RAs)	Placebo
Zhou ¹⁰⁶	2017	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Non-industry	0/6	5	2004-2014	Adult patients with an ischaemic stroke, haemorrhagic stroke or transient ischaemic attack	Oxcarbazepine	Placebo
Zonneveld ¹⁰⁷	2018	Cochrane Database of Systematic Reviews	6.8	Medicine, General & Internal	Not reported	0/7	11	1970-2017		Blood pressure-lowering drugs (BPLDs) - 5 types	Placebo, no treatment
General Medicine (n = 33)											
López-López ¹⁰⁸	2017	BMJ	23.6	Medicine, General & Internal	Non-industry	0/8	23	1989-2014	Adults with non-valvular atrial fibrillation	Direct acting oral anticoagulants - 5 types, vitamin K antagonists, antiplatelet agents	Network Meta-analysis
Wang ¹⁰⁹	2018	BMJ Open	2.4	Medicine, General & Internal	Non-industry	0/8	14	1977-2017	Children and adults with uncomplicated skin abscesses	Antibiotics - 10 types	No treatment, other antibiotics - Network meta-analysis
Cipriani ¹¹⁰	2018	Lancet	53.3	Medicine, General & Internal	Non-industry	4/18	522	1979- Unpublishe d	Adults (18 years and over) with major depressive disorder	Antidepressants - 21 types	Placebo - Network meta-analysis

Chen ¹¹¹	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/3	9	2009-2017	Patients with sepsis Patients with hormone receptor-positive or human epidermal growth factor receptor 2 negative advanced breast cancer	Statins - 3 types	Placebo
Ding ¹¹²	2018	Medicine	2.0	Medicine, General & Internal	No funding	0/6	6	2014-2017	Adults undergoing total knee arthroplasty (TKA)	Cyclin-dependent kinases 4/6 inhibitors - 3 types	Placebo
Guo ¹¹³	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/8	5	2004-2017	Patients with myocardial infarction	Tranexamic acid (TXA)	Placebo, no treatment
Han ¹¹⁴	2018	Medicine	2.0	Medicine, General & Internal	Not reported	0/7	18	2007-2016	Patients with acute coronary syndrome, percutaneous coronary intervention, or coronary stents given combination therapy with aspirin and clopidogrel	Statins - 3 types	Placebo
Hu ¹¹⁵	2018	Medicine	2.0	Medicine, General & Internal	Not reported	0/5	4	2010-2016	Patients with pterygium or glaucoma	Proton pump inhibitors Antivascular endothelial growth factor agents - 3 included	Placebo
Huang ¹¹⁶	2018	Medicine	2.0	Medicine, General & Internal	Not reported	0/5	18	2010-2015	Patients with diabetic peripheral neuropathy	Fasudil + methylcobalamin or lipoic acid	Methylcobalamin or lipoic acid alone
Jiang ¹¹⁷	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/5	13	2010-2017	Adult women with pathologically confirmed epithelial ovarian cancer	Antiangiogenic therapy (7 included) alone or combined with chemotherapy	Placebo or chemotherapy alone
Jiang ¹¹⁸	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/4	15	2011-2016	Patients with advanced non-small cell lung cancer	Immune checkpoint inhibitors: anti-PD1/PD-L1 therapies - 3 types	Chemotherapy - 6 regimens
Khan ¹¹⁹	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/8	7	2015-2017	Patients undergoing total knee or hip arthroplasty	Acetaminophen	Normal saline or placebo
Liang ¹²⁰	2017	Medicine	2.0	Medicine, General & Internal	No funding	0/4	3	2016-2017	Adults with social anxiety disorder	Fluvoxamine	Placebo
Liu ¹²¹	2018	Medicine	2.0	Medicine, General & Internal	No funding	0/7	5	1999-2007	Children and adults requiring nasogastric intubation	Lidocaine	Normal saline, K-Y lubricant gel, or no treatment
Lor ¹²²	2017	Medicine	2.0	Medicine, General & Internal	No funding	0/8	10	1999-2015	Adults with intertrochanteric fractures preparing for internal fixation	Tranexamic acid	Placebo, no treatment
Wang ¹²³	2017	Medicine	2.0	Medicine, General & Internal	No funding	0/2	4	2015-2017			

									(dynamic hip screws, proximal femoral nail antirotations)		
Wang ¹²⁴	2018	Medicine	2.0	Medicine, General & Internal	No funding	0/5	18	2001-2016	Patients with hepatorenal syndrome	Terlipressin	Placebo, octreotide, norepinephrine, dopamine + furosemide, octreotide + midodrine
Wang ¹²⁵	2018	Medicine	2.0	Medicine, General & Internal	Not reported	0/3	4	1993-2011	Patients undergoing bronchoscopy	Propofol	Midazolam Chemotherapy, everolimus, ipilimumab
Wei ¹²⁶	2017	Medicine	2.0	Medicine, General & Internal	Not reported	0/2	14	2015-2017	Cancer patients Women of reproductive age with primary dysmenorrhea	PD-1 inhibitors - 2 types Non-steroidal anti-inflammatory drugs, analgesics, oral contraceptives	
Woo ¹²⁷	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/7	34 ^P	1998-2017	Patients who were administered xenon versus propofol as a general anesthetic	Xenon	Acupuncture
Xia ¹²⁸	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/6	13	2004-2012	Patients prepared for primary total hip arthroplasty (THA)		Propofol
Yang ¹²⁹	2017	Medicine	2.0	Medicine, General & Internal	Not reported	0/4	7	2008-2016	Patients undergoing laparoscopic cholecystectomy	Glucocorticoids - 3 types	Placebo, no treatment
Ye ¹³⁰	2017	Medicine	2.0	Medicine, General & Internal	Not reported	0/3	5	2004-2016	Adults with acute heart failure	Ketamine	Placebo
Yu ¹³¹	2018	Medicine	2.0	Medicine, General & Internal	No funding	0/6	8	2009-2017	Patients with locoregionally advanced nasopharyngeal carcinoma	Serelaxin	Placebo
Yuan ¹³²	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/9	31	1995-2016		Neoadjuvant chemotherapy regimens - 16 included Aspirin, aspirin + dipyridamole, aspirin + clopidogrel, aspirin + warfarin, cilostazol, warfarin, and ticlopidine	Network meta-analysis
Zhang ¹³³	2018	Medicine	2.0	Medicine, General & Internal	Not reported	0/2	13	2001-2014	Adults with cerebral infarction Healthy volunteers and people with congestive heart failure		Placebo, other conventional therapy medicines - 3 types
Zhang ¹³⁴	2018	Medicine	2.0	Medicine, General & Internal	Non-industry	0/8	10	1989-2006	Adult patients prepared to undergo laparoscopic cholecystectomy	Histamine H2 antagonists - 5 types	
Zhao ¹³⁵	2018	Medicine	2.0	Medicine, General & Internal	Not reported	0/7	5	2008-2017	Patients with a diagnosis of	Lidocaine	Placebo, saline
Zhao ¹³⁶	2018	Medicine	2.0	Medicine, General & Internal	No funding	0/3	4	2013-2017		Nefopam	Saline or usual care

Zhou ¹³⁷	2018	Medicine	2.0	Medicine, General & Internal	No funding	0/4	6	2013-2017	symptomatic cholelithiasis and acute cholecystitis who prepared for laparoscopic cholecystectomy Adults with end-staged knee osteoarthritis undergoing total knee arthroplasty	Dexamethasone	Placebo, no treatment
Zhu ¹³⁸	2018	Medicine Postgraduate	2.0	Medicine, General & Internal	Not reported	0/3	8	2002-2016	Patients who underwent total hip arthroplasty	Selective non-steroidal anti-inflammatory drugs (selective COX-2 inhibitors) - 4 types	Non-selective non-steroidal anti-inflammatory drugs (non-selective COX-2 inhibitors) - 4 types
Zhou ¹³⁹	2018	Medicine	2.1	Medicine, General & Internal	No funding	0/5	10	2007-2017	Patients with dyslipidemia	Anacetrapib	Placebo, placebo + usual care
Zhang ¹⁴⁰	2018	Revista da Associação Médica Brasileira	0.7	Medicine, General & Internal	Non-industry	Not reported/6	6	2012-2016	Patients with complicated intra-abdominal infections and complicated urinary tract infections	Ceftazidime-avibactam	Other antibiotics - 3 types, usual care

Specialty medicine (n = 100)

Li ¹⁴¹	2018	Acta Ophthalmologica	3.3	Ophthalmology	Non-industry	Not reported/3	72	1995-2015	Patients with primary open-angle glaucoma or ocular hypertension	Prostaglandin analogues, alpha-2 adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, miotics	Placebo - Network meta-analysis
Tarantini ¹⁴²	2018	American Heart Journal	4.2	Cardiac & Cardiovascular Systems	No funding	0/7	5	2007-2016	Patients with acute coronary syndrome	P2Y12 receptor inhibitors - 2 types	Clopidogrel
Wang ¹⁴³	2018	American Journal of Cardiovascular Drugs	2.7	Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy	Non-industry	0/3	5	2014-2017	Adults aged 18–65 years with hyperlipidemia	Inclisiran	Placebo, other lipid-lowering agents - Network meta-analysis
Aman ¹⁴⁴	2018	Anaesthesia and Intensive Care	1.7	Anesthesiology; Critical Care Medicine	Non-industry	Not reported/5	10	1995-2015	Patients undergoing caesarean section under general anaesthesia	Opioid analgesics - 3 types, non-opioid analgesics - 5 types	Placebo
Li ¹⁴⁵	2018	Autoimmunity Reviews	8.7	Immunology	Non-industry	0/7	15	2004-2017	Patients with rheumatoid arthritis	Statins - 2 types	Conventional treatment, placebo + conventional treatment
Wang ¹⁴⁶	2018	Biomed Research International	2.6	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Non-industry	0/4	15	2006-2017	Patients with left ventricular dysfunction undergoing cardiac surgery	Levosimendan	Placebo, milrinone, dopamine, intra-aortic balloon pump (IABP), and standard inotropic agents

Veettil ¹⁴⁷	2017	BMC Cancer	3.3	Oncology	No funding	0/6	8	2003-2014	Adults with history of colorectal cancer or adenoma	Aspirin, non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) Purine-like xanthine oxidase inhibitors - 2 types, non-purine-like xanthine oxidase inhibitors - 2 types	Placebo, no treatment
Bredemeier ¹⁴⁸	2018	BMC Cardiovascular Disorders	1.8	Cardiac & Cardiovascular Systems	No funding	0/9	91	1973-2017	Adults under treatment for any clinical condition Patients with post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)	Nonsteroidal anti-inflammatory drugs (NSAIDs) - 6 types	Placebo, no treatment
Lyu ¹⁴⁹	2018	BMC Gastroenterology	2.7	Gastroenterology & Hepatology	Non-industry	0/5	22	2003-2017	Patients with invasive fungal infections	Voriconazole	Placebo
Xing ¹⁵⁰	2017	BMC Infectious Diseases	2.6	Infectious Diseases	Non-industry	0/6	16	2001-2016	Patients undergoing total shoulder arthroplasty or reverse shoulder arthroplasty	Tranexamic acid Pharmacological agents for traumatic brain injury – 14 types, pharmacological agents for stroke – 23 types, pharmacological agents for bacterial meningitis – 1 type, pharmacological agents for intracerebral haemorrhage – 6 types, pharmacological agents for aneurysmal subarachnoid hemorrhage – 19 types	Other antifungal agents - 7 types
Kuo ¹⁵¹	2018	BMC Musculoskeletal Disorders	2.0	Orthopedics; Rheumatology	No funding	0/4	3	2015-2017	Patients with ischemic or hemorrhagic stroke, traumatic brain injury, or bacterial meningitis	Anti-fibrotic and anti-VEGF (vascular endothelial growth factor) medications - 3 types	Placebo
Beez ¹⁵²	2017	BMC Neurology	2.2	Clinical Neurology	No funding	0/3	110 ^a	1983-2015	Patients with primary or recurrent pterygium undergoing surgical removal combined with toxic agents	Prasugrel	Unspecified control
Zeng ¹⁵³	2017	BMC Ophthalmology	1.8	Ophthalmology	No funding	0/7	32	1990-2016	Patients with acute coronary syndrome and patients who underwent percutaneous coronary intervention	Ticagrelor	Placebo - Network meta-analysis
Bundhun ¹⁵⁴	2017	BMC Pharmacology & Toxicology	1.9	Pharmacology & Pharmacy; Toxicology	Non-industry	0/3	4	2013-2016			

Zhang ¹⁵⁵	2017	BMC Psychiatry	2.4	Psychiatry	No funding	0/11	47	2003-2015	People with schizophrenia or related disorders that had a duration of treatment that was no more than 1 year	Antipsychotic drugs - 12 types	Placebo - Network meta-analysis
Zhang ¹⁵⁶	2017	BMC Pulmonary Medicine	2.7	Respiratory System	No funding	0/5	19	1996-2016	Patients with acute exacerbations of chronic obstructive pulmonary disease (COPD)	Antibiotics - 17 types	Placebo - Network meta-analysis
Zhang ¹⁵⁷	2017b	BMC Pulmonary Medicine	2.7	Respiratory System	Non-industry	0/4	25	1993-2016	Preterm infants Post-menopausal women with metastatic HR-positive, HER2-negative breast cancer	Corticosteroids	Placebo
Ramos-Esquivel ¹⁵⁸	2018	Breast Cancer British Journal of Sports Medicine	1.8	Oncology; Obstetrics & Gynecology	No funding	0/4	3	2016-2017	Patients with osteoarthritis in any joint	Cyclin-dependent kinase 4/6 inhibitors - 3 types + aromatase inhibitor - 2 types	Aromatase inhibitors - 2 types
Zeng ¹⁵⁹	2018	Sport Sciences	7.9	Sport Sciences	Non-industry	0/12	36	1979-2016		Non-steroidal anti-inflammatory drugs - 9 types	Network meta-analysis FOLFOX (leucovorin + fluorouracil + oxaliplatin) + bevacizumab, FOLFIRI (leucovorin + fluorouracil + irinotecan) + bevacizumab
Shui ¹⁶⁰	2018	Cellular Physiology and Biochemistry	5.5	Cell Biology; Physiology	Not reported	0/6	4	2015-2017	Patients with metastatic colorectal cancer	FOLFOXIRI (leucovorin + fluorouracil + oxaliplatin + irinotecan) + bevacizumab	Miltefosine, paromomycin, antimonial compounds - 2 types, pentamidine, sitamaquine
Rodrigo ¹⁶¹	2018	Clinical Microbiology and Infection	5.4	Infectious Diseases; Microbiology	No funding	0/4	28	1996-2017	Patients with visceral leishmaniasis	Amphotericin B	Placebo, nonsteroidal anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic drugs (DMARDs)
Wang ¹⁶²	2018	Clinical Rheumatology	2.1	Rheumatology	Non-industry	0/3	25	2002-2014	Patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis	Tumor necrosis factor (TNF) inhibitors - 5 types, non-tumor necrosis factor (TNF) inhibitors - 2 types	Low molecular-weight heparin (LMWH) – 5 types, enoxaparin + vitamin K antagonists (VKA)
Hong ¹⁶³	2018	Critical Reviews in Oncology / Hematology	4.5	Oncology; Hematology	No funding	1/5	13	1996-2015	Adults with acute venous thromboembolism	Proprotein convertase subtilisin/kexin type 9 gene inhibitors (PCSK9i)	Rivaroxaban, unfractionated heparin (UFH)
de Carvalho ¹⁶⁴	2018	Diabetes Care	13.4	Endocrinology & Metabolism	Not reported ^f	0/3	20	2012-2017	Patients with familial or nonfamilial		Placebo, placebo + other lipid-lowering therapy

Jaafar ¹⁶⁵	2018	Digestive Diseases and Sciences	2.8	Gastroenterology & Hepatology	Not reported	0/5	17	2000-2016	hypercholesterolemia Adults (18 and over) with organic or functional dyspepsia	Rebamipide	Placebo, standard treatment, no treatment
Liu ¹⁶⁶	2018	Drug Delivery	3.1	Pharmacology & Pharmacy	Not reported	0/2	9	2002-2015	Patients with neurodegenerative movement disorders	Riluzole	Placebo
Liu ¹⁶⁷	2018	Drug Design, Development and Therapy	2.9	Chemistry, Medicinal; Pharmacology & Pharmacy	Not reported	0/5	9	2010-2016	Patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI)	Atorvastatin	Placebo
Sun ¹⁶⁸	2017	Drug Design, Development and Therapy	2.9	Chemistry, Medicinal; Pharmacology & Pharmacy	Not reported	0/5	9	2009-2016	Adults (≥ 18 years) undergoing spinal anesthesia	Dexmedetomidine	Fentanyl
Paraschakis ¹⁶⁹	2017	East Asian Archives of Psychiatry Emergency Medicine	None	Not applicable	Not reported	0/2	4	2005-2010	Adults with traumatic brain injuries and depressive disorders	Antidepressants - 2 types	Placebo
D'Souza ¹⁷⁰	2018	Journal	2.0	Emergency Medicine	No funding	0/8	4	2001-2016	Patients taking acute antiemetic drugs	Diphenhydramine	Placebo
Mei ¹⁷¹	2016	European Journal of Gynecological Oncology	0.6	Oncology; Obstetrics & Gynecology	Not reported	Not reported/4	4	2004-2013	Adult women with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have achieved complete clinical remission after debulking surgery and first-line chemotherapy	CA125-targeted antibody – 2 types	Placebo
Verberkt ¹⁷²	2017	European Respiratory Journal Expert Opinion on Pharmacotherapy	12.2	Respiratory System	Non-industry	3/9 ^s	35	1982-2015	Patients with chronic breathlessness	Opioids - 8 types	Placebo
Sridharan ¹⁷³	2018	Expert Review of Clinical Pharmacology	3.5	Pharmacology & Pharmacy	No funding	0/3	51	1980-2016	Critically ill patients receiving stress ulcer prophylaxis (SUP)	Antacids, proton pump inhibitors (PPI), histamine-2 receptor antagonists (H2RA), and sucralfate	Placebo - Network meta-analysis
Habibi ¹⁷⁴	2018	Pharmacology	2.8	Pharmacology & Pharmacy	No funding	0/4	5	1999-2012	Patients undergoing coronary artery bypass surgery	Lidocaine	Placebo
Li ¹⁷⁵	2018	Expert Review of Clinical Pharmacology	2.8	Pharmacology & Pharmacy	Non-industry	0/4	14	2002-2017	Patients with stable angina pectoris requiring elective percutaneous	Nicorandil	Placebo (saline, isosorbide dinitrate), no treatment

Sangroongruang sri ¹⁷⁶	2018	Expert Review of Clinical Pharmacology	2.8	Pharmacology & Pharmacy	Non- industry	0/5	11	2010-2017	coronary intervention (PCI) Patients diagnosed with retinal vein occlusion	Anti-vascular endothelial growth factor (VEGF) drugs - 3 types	Sham injection - Network meta-analysis	
Hickey ¹⁷⁷	2018	Foot and Ankle Surgery	1.5	Orthopedics Oncology; Gastroenterology & Hepatology	Not reported	0/7	7	1993-2015	Adult patients with foot or ankle trauma treated with below knee cast or splint immobilization	Low molecular weight heparin - 5 types	Placebo, no treatment	
Zhao ¹⁷⁸	2018	Gastric Cancer	5.0		Non- industry	0/9	16	2002-2017	Patients with advanced gastric cancer	Targeted agents - 11 types, targeted agents + chemotherapy	Placebo - Network meta-analysis	
Khera ¹⁷⁹	2018	Gastroenterolog y	20.8	Gastroenterology & Hepatology	No funding	0/9	29	1998-2015	Obese and overweight adults (18 years and over)	Orlistat, loracaserin, naltrexone-bupropion, phentermine-topiramate, liraglutide	Placebo - Network meta-analysis	
Li ¹⁸⁰	2018	Gynecologic Oncology	4.5	Oncology; Obstetrics & Gynecology Gastroenterology & Hepatology;	Non- industry	0/6	7	2005-2016	Patients with low- risk gestational trophoblastic neoplasia (LRGTN)	Methotrexate (MEX) based chemotherapy regimens, actinomycin-d (Act-D) based chemotherapy regimens	Network meta-analysis	
Zhuge ¹⁸¹	2018	Helicobacter Indian Journal of Cancer	4.1	Microbiology	Non- industry	0/6	18	1999-2016	Patients with helicobacter pylori infection	Furazolidone	Other antibiotics - 7 types	
Kim ¹⁸²	2017	Indian Journal of Cancer	0.7	Oncology	No funding	0/4	21	1993-2011	Adults at risk of developing cancer	Statins - 7 types	Placebo	
Garg ¹⁸³	2018	Indian Journal of Gastroenterolog y	None	Not applicable	Not reported	0/4	6	2007-2016	Patients undergoing endoscopic retrograde cholangiopancreatog raphy	Immunosuppressed haematology- oncology patients	Indomethacin	Placebo
Rosanova ¹⁸⁴	2017	Infectious Diseases	1.9	Infectious Diseases	Not reported	0/5	7	2002-2011	Adults (17 years and over) diagnosed with acute gout	Voriconazole	Other antifungal agents or placebo	
Yu ¹⁸⁵	2018	Inflammopharm acology	3.3	Immunology; Toxicology	Non- industry	0/6	3	2007-2016	Patients with chronic venous disorders (CVD) or venous edema	Prednisolone	Non-steroidal anti- inflammatory drugs (NSAIDs) - 2 types	
Kakkos ¹⁸⁶	2018	International Angiology International Immunopharma cology	1.2	Peripheral Vascular Disease Immunology; Pharmacology & Pharmacy	Not reported	2/2	7	1982-2015	Adults with moderate-to-severe atopic dermatitis	Micronized purified flavonoid faction (Daflon)	Placebo	
Ou ¹⁸⁷	2018	International Immunopharma cology	3.1	Immunology; Pharmacology & Pharmacy	No funding	Not reported/5	8	2014-2017	Children diagnosed with recurrent respiratory tract infections (RRTIs)	Dupilumab	Placebo	
Yin ¹⁸⁸	2018	International Immunopharma cology	3.1	Immunology; Pharmacology & Pharmacy	No funding	0/4	53	1984-2017		Broncho-Vaxom	Placebo, routine therapies	

Zhu ¹⁸⁹	2018	International Journal of Clinical Oncology	2.6	Oncology	Non-industry	0/7	35	2005-2016	Cancer patients	Anti-EGFR monoclonal antibodies (EGFR-MoAbs)	Placebo, usual care
Liu ¹⁹⁰	2018	International Journal of Neuroscience	1.8	Neurosciences	Not reported	0/2	4	2007-2016	Patients with seizures	Lacosamide	Placebo
Coccolini ¹⁹¹	2018	International Journal of Surgery	2.7	Surgery	No funding	0/12	15	1993-2014	Patients with advanced gastric and esophago-gastric cancer	Neoadjuvant chemotherapy (with surgery)	No neoadjuvant chemotherapy (only surgery) Placebo, no treatment ("nothing controlled multimodal analgesia method")
Fan ¹⁹²	2018	International Journal of Surgery	2.7	Surgery	Non-industry	0/8	7	2005-2016	Patients with scheduled total knee arthroplasty	Dexamethasone	Patients with a diagnosis of symptomatic cholelithiasis and acute cholecystitis who prepared for laparoscopic cholecystectomy
Li ¹⁹³	2018	International Journal of Surgery	2.7	Surgery	No funding	0/5	6	2008-2017	Patients undergoing anaesthesia as part of endoscopic retrograde cholangiopancreatography	Lidocaine	Placebo, saline
Li ¹⁹⁴	2018	International Journal of Surgery	2.7	Surgery	No funding	0/4	17	1998-2017	Patients undergoing total knee arthroplasty or total hip arthroplasty	Anaesthetic medications - 12 types	No drug - Network meta-analysis
Liu ¹⁹⁵	2018	International Journal of Surgery	2.7	Surgery	Non-industry	0/5	3 ¹	2005-2017	Patients with symptomatic knee osteoarthritis	Tranexamic acid	Aminocaproic acid
Ran ¹⁹⁶	2018	International Journal of Surgery	2.7	Surgery	No funding	0/5	5	2002-2016	Patients with hepatocellular carcinoma	Hyaluronic acid	Methylprednisolone
Zhao ¹⁹⁷	2018	International Journal of Surgery	2.7	Surgery	No funding	0/3	4 ^u	2010-2017	Adult patients prepared for laparoscopic cholecystectomy	Anthracyclines	Platinum
Zhu ¹⁹⁸	2018	International Journal of Surgery	2.7	Surgery	Non-industry	0/5	6	2004-2017	Adults with major depressive disorder	Ketamine	Saline
Wagner ¹⁹⁹	2018	Journal of Affective Disorders	3.8	Clinical Neurology; Psychiatry	Non-industry	Not reported/6	119	1990-2017	Adults with major depressive disorder	Second generation antidepressants - 16 types	Placebo - Network meta-analysis
Hickman ²⁰⁰	2018	Journal of Assisted Reproduction and Genetics	2.8	Genetics & Heredity; Obstetrics & Gynecology;	Not reported	0/5	10	2007-2016	Women with lymphoma, ovarian cancer, or breast	Gonadotropin-releasing hormone agonists (GnRHa) - 7 types	Standard treatment (chemotherapy only)

Luo ²⁰¹	2018	Journal of Cancer Research and Clinical Oncology	3.3	Oncology	Reproductive Biology	Non-industry	0/4	8	2015-2017	cancer undergoing chemotherapy	Patients with non-small-cell lung carcinoma	Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors - 3 types	Chemotherapy - 2 types
Wang ²⁰²	2018	Journal of Cancer Research and Clinical Oncology	3.3	Oncology		Non-industry	0/5	26	2010-2017	Patients with metastatic castration-resistant prostate cancer		Targeted agents - 16 types	Placebo - Network meta-analysis
Wang ²⁰³	2018	Journal of Cancer Research and Therapeutics	0.8	Oncology		No funding	0/4	35	1997-2011	Cancer patients with moderate to severe pain	Adults (18 years and over) undergoing any type of cardiac surgery	Fentanyl	Morphine Placebo, discontinuation of aspirin greater than 7 days before surgery
Aboul-Hassan ²⁰⁴	2017	Journal of Cardiac Surgery	1.2	Cardiac & Cardiovascular Systems; Surgery	Cardiac & Cardiovascular Systems; Surgery	No funding	0/8	12	1985-2016			Aspirin	
Wang ²⁰⁵	2018	Journal of Cardiovascular Surgery	1.2	Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease		Not reported	0/6	5	1999-2010	Patients undergoing isolated coronary artery bypass graft (CABG) surgery		Statins - 3 types Antiandrogens, insulin sensitizers, estrogen-progestin oral contraceptives pills (OCPs), OCPs + antiandrogen, OCPs + insulin sensitizer, antiandrogen + insulin sensitizer	No preoperative statin
Barrionuevo ²⁰⁶	2018	Journal of Clinical Endocrinology and Metabolism	5.8	Endocrinology & Metabolism		Non-industry	0/8	32	1989-2016	Women with hirsutism			Placebo - Network meta-analysis
Cui ²⁰⁷	2018	Journal of Clinical Pharmacy and Therapeutics	1.7	Pharmacology & Pharmacy		Not reported	0/6	23	1993-2014	Patients with type 2 diabetes	Adults with moderate-to-severe chronic plaque-type psoriasis	Statins - 6 types	Placebo - Network meta-analysis
Sawyer ²⁰⁸	2018	Journal of Dermatological Treatment	2.1	Dermatology		Industry	6/6 ^v	54	2001-2016	Patients with onset of atrial fibrillation (AF) within 48 h, who were hemodynamically stable and without evidence of acute coronary syndrome,		Apremilast, biological therapies - 7 types	Placebo - Network meta-analysis
Markey ²⁰⁹	2018	Journal of Emergency Medicine	1.2	Emergency Medicine		Not reported	Not reported/3	11	1989-2004			Flecainide	Placebo, verapamil, and other active anti-dysrhythmics

Szabó ²¹⁰	2017	Journal of Gastrointestinal and Liver Diseases	2.0	Gastroenterology & Hepatology	Not reported	0/15	10 ^w	2009-2016	congestive heart failure, or structural heart disease Adult patients (18 years and over) taking low-dose aspirin for a minimum of 2 weeks Patients with histologically confirmed solid cancer	Proton-pump inhibitors (PPIs) - 5 types	Histamine-2 receptor antagonists (H2RAs) - 2 types
Su ²¹¹	2018	Journal of Immunology Research	3.3	Immunology	Non-industry	0/6	15	2011-2017	Patients with histologically confirmed solid cancer	Immune checkpoint inhibitors (ICIs) - 5 types	Placebo or chemotherapy
Chen ²¹²	2018	Journal of Interventional Cardiac Electrophysiology	1.5	Cardiac & Cardiovascular Systems	Non-industry	0/9	8	2006-2017	Patients with persistent atrial fibrillation	Antiarrhythmic drugs	Catheter ablation
Chen ²¹³	2017	Journal of Orthopaedic Surgery and Research	1.6	Orthopedics	No funding	0/4	6	2008-2014	Patients undergoing knee arthroscopy	Midazolam	Placebo
Li ²¹⁴	2018	Journal of Orthopaedic Surgery and Research	1.6	Orthopedics	Not reported	0/5	3 ^x	2002-2017	Patients undergoing a primary total hip or knee arthroplasty	Aminocaproic acid	Placebo or no treatment
Luo ²¹⁵	2018	Journal of Orthopaedic Surgery and Research	1.6	Orthopedics	Not reported	0/4	3 ^y	2002-2017	Patients treated with spine surgery	Tranexamic acid	Control (not specified)
Ma ²¹⁶	2018	Journal of Orthopaedic Surgery and Research	1.6	Orthopedics	No funding	0/4	4	1991-2015	Patients who underwent hip surgery	Naproxen	Placebo
He ²¹⁷	2018	Journal of Psychiatric Research	4.0	Psychiatry	Non-industry	0/8	22	2009-2015	Patients with a primary diagnosis of major depressive disorder (MDD)	Vortioxetine, levomilnacipran, vilazodone	Placebo
Wang ²¹⁸	2018	Journal of Stroke & Cerebrovascular Diseases	1.6	Neurosciences; Peripheral Vascular Disease	Non-industry	4/8	6	2003-2013	Asian patients with non-valvular atrial fibrillation (AF)	Warfarin, direct oral anticoagulants (DOACs) - 5 types	Network meta-analysis
Dhana ²¹⁹	2018	Journal of the American Academy of Dermatology	6.9	Dermatology	No funding	0/6	15	2000-2016	People with scabies	Permethrin Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors - 2 types	Ivermectin
Karatasakis ²²⁰	2017	Journal of the American Heart Association	4.5	Cardiac & Cardiovascular Systems	Not reported	3/12 ^z	35	2012-2017	Adults with hypercholesterolemia	PCSK9 inhibitors - 2 types	Placebo, ezetimibe, standard therapy

Kuo ²²¹	2018	Journal of the European Academy of Dermatology and Venereology	4.3	Dermatology	Non-industry	2/4	4	2012-2016	Adult patients (≥ 18) with moderate-to-severe plaque psoriasis	Tofacitinib	Placebo
Liu ²²²	2016	Journal of Traditional Chinese Medicine	0.9	Integrative & Complementary Medicine Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Non-industry	Not reported/6	16	2005-2015	Patients with rheumatoid arthritis	Methotrexate	Sinomenine
Zheng ²²³	2017	Journal of Zhejiang University-SCIENCE B	1.8	Critical Care Medicine; Respiratory System	Not reported	0/7	8	1990-2014	Adult patients undergoing cardiac surgery requiring aortic cross-clamp Patients with isoniazid-resistant, rifampicin-susceptible tuberculosis	Amiodarone, lidocaine Fluoroquinolone, streptomycin	Placebo Usual care (REZ = rifampicin, ethambutol, pyrazinamide)
Fregonese ²²⁴	2018	Lancet Respiratory Medicine	21.5	Clinical Neurology; Neurosciences	Non-industry	0/57	2	2010-2014 2010- Unpublished	Patients during early post-stroke period Patients arranged for primary trabeculectomy	Cerebrolysin Bevacizumab, bevacizumab + antimetabolite - 2 types	Placebo Placebo, antimetabolite - 2 types
Bornstein ²²⁵	2018	Neurological Research	2.3	Clinical Neurology	No funding	Not reported/10	9	2013-2015	Patients undergoing spinal surgery	Gabapentin	Placebo
Chen ²²⁶	2018	Ophthalmic Research	1.8	Anesthesiology; Clinical Neurology	No funding	0/4	3	2004-2016	Adult patients undergoing surgical procedures	Dexmedetomidine + opioids	Opioids
Han ²²⁷	2017	Pain Physician	2.6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Not reported	0/5	18	2004-2016	Patients with tuberculosis	V-5 immunitor	Usual care (chemotherapy), usual care + placebo
Peng ²²⁸	2017	Pain Physician	2.6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Not reported	0/7	2 ^{aa}	2011-2012	Patients with non-cystic fibrosis bronchiectasis	Antibiotics - 7 types	Placebo, symptomatic treatment only
Feng ²²⁹	2016	Pharmazie	1.0	Parasitology; Tropical Medicine	Not reported	Not reported/8	12	1999-2014	Patients infected with soil transmitted helminths	Albendazole + ivermectin	Albendazole, ivermectin
Xu ²³⁰	2016	Pharmazie PLOS Neglected Tropical Diseases	1.0		Non-industry	0/9	14 ^{bb}	1997-2015			
Palmeirim ²³¹	2018		4.4								

Furukawa ²³²	2018	Psychotherapy and Psychosomatics	13.1	Psychiatry; Psychology	Non-industry	2/11	3	2000-2015	Adults with persistent depressive disorder (DSM-5), chronic major depression, recurrent major depression with incomplete interepisode recovery or dysthymia (DSM-IV), or any corresponding conditions	Antidepressants - 6 types, cognitive-behavioral analysis system of psychotherapy, combination of antidepressants and cognitive-behavioral analysis system of psychotherapy	Network meta-analysis
Liu ²³³	2018	Renal Failure	1.4	Urology & Nephrology	Not reported	0/6	12	2006-2015	Adult patients with chronic kidney disease	Uric acid-lowering therapy - 2 types	Placebo, usual therapy, no treatment
Miravittles ²³⁴	2017	Respiratory Research	3.8	Respiratory System	Industry	3/4	10	2014-2016	Adults with a history of chronic obstructive pulmonary disease (COPD)	Tiotropium + olodaterol	Tiotropium or olodaterol as monotherapy, salmeterol + fluticasone
Wang ²³⁵	2017	Respiratory Research	3.8	Respiratory System	Non-industry	1/7	6	2006-2016	Patients with intermittent or mild persistent asthma	Corticosteroids, fast-onset-acting β -agonists	Corticosteroid + fast-onset-acting β -agonist
Kawalec ²³⁶	2018	Rheumatology International	2.0	Rheumatology	No funding	0/4	8	2011-2016	Adults (18 years and over) with moderate to severe psoriatic arthritis (PsA)	Tumor necrosis factor (antiTNF)- α inhibitors - 4 types	Placebo - Network meta-analysis
Malhotra ²³⁷	2018	Stroke Surgical Laparoscopy Endoscopy & Percutaneous Techniques	6.2	Clinical Neurology; Peripheral Vascular Disease	Not reported	0/6	12	2009-2016	Adult patients (18 years and over) treated for the secondary prevention of cardiovascular, peripheral vascular, and cerebrovascular disease	Proton pump inhibitors (PPI) + thienopyridines	Thienopyridines - 2 types
Zhang ²³⁸	2018	Surgery	1.0	Surgery	Not reported	0/3	5	1995-2018	Adults (18 and over) undergoing gastrointestinal endoscopy	Midazolam	Propofol
Yamashita ²³⁹	2018	Thrombosis Research	2.8	Hematology; Peripheral Vascular Disease	No funding	3/7	6	2009-2014	Asian and non-Asian adults (18 years and older) with acute venous thromboembolism	Direct oral anticoagulants (DOACs) - 4 types	Vitamin K antagonists (VKAs), heparin
Zhang ²⁴⁰	2018	Vaccine	3.3	Immunology; Medicine, Research & Experimental	No funding	1/6	13	1999-2014	HIV-positive people	Influenza vaccine, Placebo	Network meta-analysis

Multidisciplinary sciences (n = 10)											
Chen ²⁴¹	2018	Medical Science Monitor	1.9	Medicine, Research & Experimental	Non-industry	0/5	20 ^{cc}	2000-2016	Patients with essential hypertension Adult patients (over 18 years old) that underwent the extraction of any tooth	Anti-hypertensive drugs - 8 types	Acupuncture
Arteagoitia ²⁴²	2018	PLOS ONE	2.8	Multidisciplinary Sciences	No funding	0/3	8	1989-2015	Adults with osteoarthritis or rheumatoid arthritis of the knee or hip	Chlorhexidine	Placebo, standard treatment
Feng ²⁴³	2018	PLOS ONE	2.8	Multidisciplinary Sciences	No funding	0/4	9	2002-2009	Pediatric surgical patients	Etoricoxib	Placebo, other non-steroidal anti-inflammatory drugs (NSAIDs) - 2 included
Kawakami ²⁴⁴	2018	PLOS ONE	2.8	Multidisciplinary Sciences	Non-industry	0/5	6	2007-2017	Adults (18 years and over) diagnosed with generalized anxiety disorder (GAD)	Magnesium	Placebo, no treatment
Li ²⁴⁵	2018	PLOS ONE	2.8	Multidisciplinary Sciences	Non-industry	0/7	8	2007-2014	Patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis	Duloxetine	Placebo
Lin ²⁴⁶	2017	PLOS ONE	2.8	Multidisciplinary Sciences	Non-industry	0/6	21	1992-2012	Adults (19 years and over) undergoing cardiac surgery	Calcium channel blockers	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers
Ling ²⁴⁷	2018	PLOS ONE	2.8	Multidisciplinary Sciences	Non-industry	Not reported/6	9	2003-2017	Cancer patients	Dexmedetomidine	Propofol, morphine, placebo
Rohner ²⁴⁸	2017	PLOS ONE	2.8	Multidisciplinary Sciences	Non-industry	2/7	94	1993-2014	Post renal transplant patients	Erythropoiesis-stimulating agents	Usual care
Sethi ²⁴⁹	2018	PLOS ONE	2.8	Multidisciplinary Sciences	No funding	0/6	28	1986-2017	Patients with atrial fibrillation or atrial flutter	Digoxin	Placebo, no intervention, beta blockers, calcium antagonists, amiodarone
Wolf ²⁵⁰	2018	PLOS ONE	2.8	Multidisciplinary Sciences	Industry	1/9	13	2002-2016	Patients with atrial fibrillation or atrial flutter	mTOR-inhibitors - 2 types	Calcineurin-inhibitors

^aOnly 3 studies reported that authors were employed by industry and therefore we included them as ties for the purposes of this table; ^b11/12 included RCTs had a drug arm; ^c33/38 included RCTs had a drug arm; ^d4/14 included RCTs had a drug arm; ^eOne author reported pharmaceutical company employment; ^f9/11 included RCTs had a drug arm; ^g71/120 included studies were RCTs; ^h24/25 included studies were RCTs; ⁱMeta-analysis funding sources reported as 'None, Other' we coded as no study funding; ^j10/27 included RCTs had a drug arm; ^kFlow chart indicates that 0 RCTs were included in the quantitative synthesis, but 2 RCTs were quantitatively synthesized and 13 were included; ^lDeclarations of interest were provided for only 3 out of 5 meta-analysis authors; ^m24/31 included RCTs had a drug arm; ⁿ103/106 included RCTs had a drug arm; ^o3/5 included RCTs had a drug arm; ^p34/60 included RCTs had a drug arm; ^q110/123 included RCTs had an eligible drug arm; ^rSalary was reported under 'funding' but they did not specify whether there was any funding for the study itself; ^sICMJE forms only provided for 5/9 authors; ^t3/4 included studies were RCTs; ^u4/11 included studies were RCTs; ^vFour authors reported financial ties with a pharmaceutical company and employment by Symmetron, a company that provides health economic research services to pharmaceutical companies, and two authors reported employment by a pharmaceutical company; ^w10/12 included studies were RCTs; ^x3/7 included studies were RCTs; ^y3/4 included studies were RCTs; ^zOf the 3 authors that reported financial ties, one also reported industry employment; ^{aa}2/4 included studies were RCTs; ^{bb}14/30 included studies were RCTs; ^{cc}20/30 included studies were RCTs with a drug arm

eTable2. – Detailed reporting of study funding sources (F), author-industry financial ties (T), and author-industry employment (E) from included RCTs

First Author	Year	Journal	Funding Sources of Included Trials Reported in Meta-analysis?	Author-Industry Financial Ties of Included Trials Reported in Meta-analysis?	Author-Industry Employment of Included Trials Reported in Meta-analysis?	Location Reported						
						Risk of Bias Text	Risk of Bias Figure or Table	Main Text, Other than Risk of Bias	Other in Main Document (Characteristics of Included Studies Table, other table, footnote)	Abstract	Lay summary	Online appendix
Cochrane Reviews (n = 107)												
Abdel-Rahman ¹	2018	Cochrane Database of Systematic Reviews	Full	No	No	F	F		F	F	F	
Adams ²	2018	Cochrane Database of Systematic Reviews	Full	No	No	F		F	F			
Agabio ³	2018	Cochrane Database of Systematic Reviews	Full	Partial	No			F, T	F, T		F	
Al-Shahi Salman ⁴	2018	Cochrane Database of Systematic Reviews	Partial	No	No			F	F			
Alabed ⁵	2018	Cochrane Database of Systematic Reviews	Partial	No	Partial				F, E			
Allegretti ⁶	2017	Cochrane Database of Systematic Reviews	Full	No	No	F	F			F	F	
Arechabala ⁷	2018	Cochrane Database of Systematic Reviews	Full	Partial	Partial	F	F, E	F, T	F, T, E		F	
Baandrup ⁸	2018	Cochrane Database of Systematic Reviews	Full	Full	Partial	F	F	F	F, T, E		F	
Bala ⁹	2018	Cochrane Database of Systematic Reviews	Full	No	No	F			F			
Barbato ¹⁰	2018	Cochrane Database of Systematic Reviews	No	No	No							
Bergman ¹¹	2018	Cochrane Database of Systematic Reviews	Full	Partial	No				F, T			
Bighelli ¹²	2018	Cochrane Database of Systematic Reviews	Full	Full	Partial	F	F, T, E	F	F, T, E	F	F	
Birks ¹³	2018	Cochrane Database of Systematic Reviews	Full	Partial	No			F	F, T	F		
Boyapati ¹⁴	2018	Cochrane Database of Systematic Reviews	No	No	No							
Brown ¹⁵	2018	Cochrane Database of Systematic Reviews	Partial	Partial	No	F	F	F	F, T	F	F	
Bruins Slot ¹⁶	2018	Cochrane Database of Systematic Reviews	Full	No	No				F			
Bryan ¹⁷	2017	Cochrane Database of Systematic Reviews	Partial	No	No				F			

Bryant-Smith ¹⁸	2018	Cochrane Database of Systematic Reviews	Full	No	No				F
Burry ¹⁹	2018	Cochrane Database of Systematic Reviews	Full	No	No	F	F		F
Campschroer ²⁰	2018	Cochrane Database of Systematic Reviews	Full	Full	No				F, T
Candy ²¹	2018	Cochrane Database of Systematic Reviews	Full	No	No		F		F
Chiew ²²	2018	Cochrane Database of Systematic Reviews	No	No	No				
Das ²³	2018	Cochrane Database of Systematic Reviews	Full	No	No		F	F	F
Demicheli ²⁴	2018	Cochrane Database of Systematic Reviews	Full ^a	Partial	Partial				F, T, E
Demicheli ²⁵	2018	Cochrane Database of Systematic Reviews	No	No	No				
Di Nisio ²⁶	2018	Cochrane Database of Systematic Reviews	Partial	Partial	No				F, T
El-Sayeh ²⁷	2018	Cochrane Database of Systematic Reviews	Full	No	No	F			F
Engelen ²⁸	2018	Cochrane Database of Systematic Reviews	No	No	No				
Eshun-Wilson ²⁹	2018	Cochrane Database of Systematic Reviews	Full	Full	No				F, T
Essali ³⁰	2018	Cochrane Database of Systematic Reviews	Full	No	No				F
Everitt ³¹	2018	Cochrane Database of Systematic Reviews	Partial	Partial	No	F, T	F, T	F	F, T
Fanshawe ³²	2017	Cochrane Database of Systematic Reviews	No	No	No				
Franik ³³	2018	Cochrane Database of Systematic Reviews	Full	Partial	No				F, T
González ³⁴	2018	Cochrane Database of Systematic Reviews	Full	No	No				F
Grabosch ³⁵	2018	Cochrane Database of Systematic Reviews	No	No	No				
Graves ³⁶	2018	Cochrane Database of Systematic Reviews	Partial ^b	No	No				F
Haas ³⁷	2018	Cochrane Database of Systematic Reviews	Full	Full	No		F, T		F, T
Hakoum ³⁸	2018	Cochrane Database of Systematic Reviews	Full	Full	No				F, T
Heras-Mosteiro ³⁹	2017	Cochrane Database of Systematic Reviews	Partial ^c	Partial ^d	Partial				F, T, E
Janmaat ⁴⁰	2017	Cochrane Database of Systematic Reviews	No	No	No				
Jefferson ⁴¹	2018	Cochrane Database of Systematic Reviews	Full	No	No				F
Jung ⁴²	2017	Cochrane Database of Systematic Reviews	Full	Full	Partial		F, T		F, T, E

Kaempfen ⁴³	2018	Cochrane Database of Systematic Reviews	No	No	No					
Kahale ⁴⁴	2017	Cochrane Database of Systematic Reviews	Full	Full	Partial ⁶				F, T, E	
Kahale ⁴⁵	2018	Cochrane Database of Systematic Reviews	Full	Partial	No				F, T	
Kahale ⁴⁶	2018	Cochrane Database of Systematic Reviews	Full	Partial	No				F, T	
Kapur ⁴⁷	2018	Cochrane Database of Systematic Reviews	Full	No	No				F	
Kelly ⁴⁸	2018	Cochrane Database of Systematic Reviews	Partial ⁷	Partial	No		F		F, T	
Knighly ⁴⁹	2017	Cochrane Database of Systematic Reviews	Full	No	No				F	
Kopsaftis ⁵⁰	2018	Cochrane Database of Systematic Reviews	No	No	No					
Lawrie ⁵¹	2018	Cochrane Database of Systematic Reviews	Full	Partial	Partial				F, T, E	
Leathersich ⁵²	2018	Cochrane Database of Systematic Reviews	Full	Full	No	F, T	F, T	F, T	F, T	
Lethaby ⁵³	2017	Cochrane Database of Systematic Reviews	Full	No	No			F	F	F
López-Briz ⁵⁴	2018	Cochrane Database of Systematic Reviews	Full	No	No				F	
Marchant ⁵⁵	2018	Cochrane Database of Systematic Reviews	Partial	No	No				F	
Matar ⁵⁶	2018	Cochrane Database of Systematic Reviews	Full	No	No		F			
Matar ⁵⁷	2018	Cochrane Database of Systematic Reviews	Full	Full	No				F, T	
McNicol ⁵⁸	2018	Cochrane Database of Systematic Reviews	Full	No	No				F	
McTague ⁵⁹	2018	Cochrane Database of Systematic Reviews	No	No	No					
Mhaskar ⁶⁰	2017	Cochrane Database of Systematic Reviews	Full	Full	Partial				F, T, E	
Milligan ⁶¹	2018	Cochrane Database of Systematic Reviews	Partial ⁸	No	No	F	F			
Monk ⁶²	2017	Cochrane Database of Systematic Reviews	Full	Full	No			F, T	F, T	
Montero ⁶³	2018	Cochrane Database of Systematic Reviews	Partial	No	No		F			
Mücke ⁶⁴	2018	Cochrane Database of Systematic Reviews	Full	Full	Partial			F, T	F, T, E	
Narula ⁶⁵	2018	Cochrane Database of Systematic Reviews	No	No	No					
Nevitt ⁶⁶	2017	Cochrane Database of Systematic Reviews	Partial	No	No			F	F	
Nevitt ⁶⁷	2018	Cochrane Database of Systematic Reviews	Full	No	No				F	

Norman ⁶⁸	2018	Cochrane Database of Systematic Reviews	Full	No	Partial			F	F, E		
Normansell ⁶⁹	2018	Cochrane Database of Systematic Reviews	Full	No ^h	No			F	F		
Novoa ⁷⁰	2018	Cochrane Database of Systematic Reviews	Full	Partial ^h	No	F	F		F, T	F	F
Ohlsson ⁷¹	2017	Cochrane Database of Systematic Reviews	Partial	No	No			F	F		
Ostinelli ⁷²	2018	Cochrane Database of Systematic Reviews	Full	No	No			F	F		
Ostinelli ⁷³	2018	Cochrane Database of Systematic Reviews	Partial	Partial	No	F	F, T	F			
Ostuzzi ⁷⁴	2018	Cochrane Database of Systematic Reviews	Full	Partial	No	F	F, T	F			
Parker ⁷⁵	2018	Cochrane Database of Systematic Reviews	No	No	No						
Pasquali ⁷⁶	2018	Cochrane Database of Systematic Reviews	Partial	Partial	No	F, T	F, T	F		F	F
Pike ⁷⁷	2018	Cochrane Database of Systematic Reviews	Full	No	No			F	F		
Rirash ⁷⁸	2017	Cochrane Database of Systematic Reviews	No	No	No						
Robertson ⁷⁹	2017	Cochrane Database of Systematic Reviews	No	No	No						
Romero ⁸⁰	2017	Cochrane Database of Systematic Reviews	Full	No	No	F	F	F	F	F	F
Rosumeck ⁸¹	2018	Cochrane Database of Systematic Reviews	Full	Full	No				F, T		
Rüschén ⁸²	2018	Cochrane Database of Systematic Reviews	Full	Full	No			F, T	F, T		
Ruthirakuhan ⁸³	2018	Cochrane Database of Systematic Reviews	Full	No	Partial			F	F, E		
Sankar ⁸⁴	2018	Cochrane Database of Systematic Reviews	No	No	No						
Schumann ⁸⁵	2018	Cochrane Database of Systematic Reviews	Full	Partial	Partial	F, T		F	F, T, E	F, T	F
Simancas-Racines ⁸⁶	2018	Cochrane Database of Systematic Reviews	Full	Full	No	F	F	F	F, T		
Smith ⁸⁷	2017	Cochrane Database of Systematic Reviews	Full	Full	Full	F, T, E	F, T, E				
Smith ⁸⁸	2018	Cochrane Database of Systematic Reviews	Full	Full	No			F, T	F, T		
Soares-Weiser ⁸⁹	2018	Cochrane Database of Systematic Reviews	Partial	No	No				F		
Squizzato ⁹⁰	2017	Cochrane Database of Systematic Reviews	Full	Partial ⁱ	No	F	F, T	F		F	
St George ⁹¹	2018	Cochrane Database of Systematic Reviews	Full	Partial	Partial	F, T	F, T, E	F	F, T, E		
Stern ⁹²	2017	Cochrane Database of Systematic Reviews	Full	No	No			F	F		F

Sturman ⁹³	2017	Cochrane Database of Systematic Reviews	Full	Full	No	F, T	F, T	F, T		
Tammenmaa-Aho ⁹⁴	2018	Cochrane Database of Systematic Reviews	Partial	No	No				F	
Temmingh ⁹⁵	2018	Cochrane Database of Systematic Reviews	Full	Partial	Partial	F, T	F, T, E	F, T, E	F, T	
Tenforde ⁹⁶	2018	Cochrane Database of Systematic Reviews	Full	Full	No	F, T	F, T		F, T	
Toews ⁹⁷	2018	Cochrane Database of Systematic Reviews	Full	Full	Partial		F, E	F	F, T	
Venekamp ⁹⁸	2018	Cochrane Database of Systematic Reviews	Full	Full	No			F	F, T	
Vermeij ⁹⁹	2018	Cochrane Database of Systematic Reviews	No	No	No					
Vietto ¹⁰⁰	2018	Cochrane Database of Systematic Reviews	Full	No	No				F	F
Wall ¹⁰¹	2018	Cochrane Database of Systematic Reviews	Full	Full	No	F, T	F	F	F	
Weibel ¹⁰²	2018	Cochrane Database of Systematic Reviews	Full	No	No			F	F	
Wright ¹⁰³	2018	Cochrane Database of Systematic Reviews	Partial	Partial	No	F	F, T			
Xiao ¹⁰⁴	2018	Cochrane Database of Systematic Reviews	Full	No	No				F	
Zhang ¹⁰⁵	2017	Cochrane Database of Systematic Reviews	Full	No	No	F	F	F	F	F
Zhou ¹⁰⁶	2017	Cochrane Database of Systematic Reviews	Full	Full	No			F	F, T	F
Zonneveld ¹⁰⁷	2018	Cochrane Database of Systematic Reviews	Partial ^l	No	No		F			
General Medicine (n = 33)										
López-López ¹⁰⁸	2017	BMJ	Full	No	No			F		F
Wang ¹⁰⁹	2018	BMJ Open	No	No	No					
Cipriani ¹¹⁰	2018	Lancet	Full ^k	No	No			F		F
Chen ¹¹¹	2018	Medicine	No	No	No					
Ding ¹¹²	2018	Medicine	No	No	No					
Guo ¹¹³	2018	Medicine	No	No	No					
Han ¹¹⁴	2018	Medicine	No	No	No					
Hu ¹¹⁵	2018	Medicine	No	No	No					
Huang ¹¹⁶	2018	Medicine	Full	Partial	No	F, T				
Jiang ¹¹⁷	2018	Medicine	No	No	No					
Jiang ¹¹⁸	2018	Medicine	No	No	No					
Khan ¹¹⁹	2018	Medicine	No	No	No					
Liang ¹²⁰	2017	Medicine	No	No	No					
Liu ¹²¹	2018	Medicine	Partial ^l	No	No			F		
Lor ¹²²	2017	Medicine	No	No	No					
Wang ¹²³	2017	Medicine	No	No	No					
Wang ¹²⁴	2018	Medicine	No	No	No					
Wang ¹²⁵	2018	Medicine	No	No	No					
Wei ¹²⁶	2017	Medicine	No	No	No					

Woo ¹²⁷	2018	Medicine	No	No	No		
Xia ¹²⁸	2018	Medicine	No	No	No		
Yang ¹²⁹	2017	Medicine	No	No	No		
Ye ¹³⁰	2017	Medicine	No	No	No		
Yu ¹³¹	2018	Medicine	No	No	No		
Yuan ¹³²	2018	Medicine	No	No	No		
Zhang ¹³³	2018	Medicine	No	No	No		
Zhang ¹³⁴	2018	Medicine	No	No	No		
Zhao ¹³⁵	2018	Medicine	No	No	No		
Zhao ¹³⁶	2018	Medicine	No	No	No		
Zhou ¹³⁷	2018	Medicine	No	No	No		
Zhu ¹³⁸	2018	Medicine	No	No	No		
Zhou ¹³⁹	2018	Postgraduate Medicine Revista da Associação Médica Brasileira	No	No	No		
Zhang ¹⁴⁰	2018	Médica Brasileira	Full	Full ^m	No	F, T	
Specialty medicine (n = 100)							
Li ¹⁴¹	2018	Acta Ophthalmologica American Heart Journal	Full ⁿ	No	No	F	F
Tarantini ¹⁴²	2018	American Journal of Cardiovascular Drugs	No	No	No		
Wang ¹⁴³	2018	Anaesthesia and Intensive Care	No	No	No		
Aman ¹⁴⁴	2018	Autoimmunity Reviews	No	No	No		
Li ¹⁴⁵	2018	Biomed Research International	No	No	No		
Wang ¹⁴⁶	2018	BMC Cancer	No	No	No		
Veetil ¹⁴⁷	2017	BMC Cardiovascular Disorders	No	No	No		
Bredemeier ¹⁴⁸	2018	BMC Gastroenterology	Full	No	No		F
Lyu ¹⁴⁹	2018	BMC Infectious Diseases	No	No	No		
Xing ¹⁵⁰	2017	BMC Musculoskeletal Disorders	No	No	No		
Kuo ¹⁵¹	2018	BMC Neurology	No	No	No		
Beez ¹⁵²	2017	BMC Ophthalmology	No	No	No		
Zeng ¹⁵³	2017	BMC Pharmacology & Toxicology	No	No	No		
Bundhun ¹⁵⁴	2017	BMC Psychiatry	No	No	No		
Zhang ¹⁵⁵	2017	BMC Pulmonary Medicine	No	No	No		
Zhang ¹⁵⁶	2017	BMC Pulmonary Medicine	No	No	No		
Zhang ¹⁵⁷	2017	Medicine	Full	No	No		
Ramos-Esquivel ¹⁵⁸	2018	Breast Cancer British Journal of Sports Medicine	No	No	No		
Zeng ¹⁵⁹	2018		Partial ^o	No	No	F	F

Shui ¹⁶⁰	2018	Cellular Physiology and Biochemistry	No	No	No		
Rodrigo ¹⁶¹	2018	Clinical Microbiology and Infection	Partial	No	No		F
Wang ¹⁶²	2018	Clinical Rheumatology	No	No	No		
Hong ¹⁶³	2018	Critical Reviews in Hematology	No	No	No		
de Carvalho ¹⁶⁴	2018	Diabetes Care	No	No	No		
Jaafar ¹⁶⁵	2018	Digestive Diseases and Sciences	No	No	No		
Liu ¹⁶⁶	2018	Drug Delivery	No	No	No		
Liu ¹⁶⁷	2018	Drug Design, Development and Therapy	No	No	No		
Sun ¹⁶⁸	2017	Drug Design, Development and Therapy	No	No	No		
Paraschakis ¹⁶⁹	2017	East Asian Archives of Psychiatry	No	No	No		
D'Souza ¹⁷⁰	2018	Emergency Medicine Journal	No	No	No		
Mei ¹⁷¹	2016	European Journal of Gynecological Oncology	No	No	No		
Verberkt ¹⁷²	2017	European Respiratory Journal	No	No	No		
Sridharan ¹⁷³	2018	Expert Opinion on Pharmacotherapy	No	No	No		
Habibi ¹⁷⁴	2018	Expert Review of Clinical Pharmacology	No	No	No		
Li ¹⁷⁵	2018	Expert Review of Clinical Pharmacology	No	No	No		
Sangroongruangsi ¹⁷⁶	2018	Expert Review of Clinical Pharmacology	Full	No	No		F
Hickey ¹⁷⁷	2018	Foot and Ankle Surgery	No	No	No		
Zhao ¹⁷⁸	2018	Gastric Cancer	Partial ^P	No	No	F	F
Khera ¹⁷⁹	2018	Gastroenterology	No	No	No		
Li ¹⁸⁰	2018	Gynecologic Oncology	No	No	No		
Zhuge ¹⁸¹	2018	Helicobacter	No	No	No		
Kim ¹⁸²	2017	Indian Journal of Cancer	No	No	No		
Garg ¹⁸³	2018	Indian Journal of Gastroenterology	No	No	No		
Rosanova ¹⁸⁴	2017	Infectious Diseases	No	No	No		
Yu ¹⁸⁵	2018	Inflammopharmacology	No	No	No		

Kakkos ¹⁸⁶	2018	International Angiology	No	No	No		
Ou ¹⁸⁷	2018	International Immunopharmacology	Full	No	No		F
Yin ¹⁸⁸	2018	International Immunopharmacology	No	No	No		
Zhu ¹⁸⁹	2018	International Journal of Clinical Oncology	No	No	No		
Liu ¹⁹⁰	2018	International Journal of Neuroscience	No	No	No		
Coccolini ¹⁹¹	2018	International Journal of Surgery	No	No	No		
Fan ¹⁹²	2018	International Journal of Surgery	No	No	No		
Li ¹⁹³	2018	International Journal of Surgery	No	No	No		
Li ¹⁹⁴	2018	International Journal of Surgery	No	No	No		
Liu ¹⁹⁵	2018	International Journal of Surgery	No	No	No		
Ran ¹⁹⁶	2018	International Journal of Surgery	No ^q	No	No		
Zhao ¹⁹⁷	2018	International Journal of Surgery	No	No	No		
Zhu ¹⁹⁸	2018	International Journal of Surgery	No	No	No		
Wagner ¹⁹⁹	2018	Journal of Affective Disorders	Partial	No	No		F
Hickman ²⁰⁰	2018	Journal of Assisted Reproduction and Genetics	No	No	No		
Luo ²⁰¹	2018	Journal of Cancer Research and Clinical Oncology	No	No	No		
Wang ²⁰²	2018	Journal of Cancer Research and Clinical Oncology	Partial ^r	No	No	F	F
Wang ²⁰³	2018	Journal of Cancer Research and Therapeutics	No	No	No		
Aboul-Hassan ²⁰⁴	2017	Journal of Cardiac Surgery	No	No	No		
Wang ²⁰⁵	2018	Journal of Cardiovascular Surgery	No	No	No		F
Barrionuevo ²⁰⁶	2018	Journal of Clinical Endocrinology and Metabolism	Full	No	No	F	

Cui ²⁰⁷	2018	Journal of Clinical Pharmacy and Therapeutics	Full*	No	No	F
Sawyer ²⁰⁸	2018	Journal of Dermatological Treatment	No	No	No	
Markey ²⁰⁹	2018	Journal of Emergency Medicine	No	No	No	
Szabó ²¹⁰	2017	Journal of Gastrointestinal and Liver Diseases	No	No	No	
Su ²¹¹	2018	Journal of Immunology Research	No	No	No	
Chen ²¹²	2018	Journal of Interventional Cardiac Electrophysiology	No	No	No	
Chen ²¹³	2017	Journal of Orthopaedic Surgery and Research	No	No	No	
Li ²¹⁴	2018	Journal of Orthopaedic Surgery and Research	No	No	No	
Luo ²¹⁵	2018	Journal of Orthopaedic Surgery and Research	No	No	No	
Ma ²¹⁶	2018	Journal of Orthopaedic Surgery and Research	No	No	No	
He ²¹⁷	2018	Journal of Psychiatric Research	Full	No	No	F
Wang ²¹⁸	2018	Journal of Stroke & Cerebrovascular Diseases	No	No	No	
Dhana ²¹⁹	2018	Journal of the American Academy of Dermatology	No	No	No	
Karatasakis ²²⁰	2017	Journal of the American Heart Association	No	No	No	
Kuo ²²¹	2018	Journal of the European Academy of Dermatology and Venereology	Full	No	No	
Liu ²²²	2016	Journal of Traditional Chinese Medicine	No	No	No	
Zheng ²²³	2017	Journal of Zhejiang University-SCIENCE B	No	No	No	
Fregonese ²²⁴	2018	Lancet Respiratory Medicine	No	No	No	
Bornstein ²²⁵	2018	Journal of Neurological Sciences	No	No	No	
Chen ²²⁶	2018	Ophthalmic Research	No	No	No	
Han ²²⁷	2017	Pain Physician	No	No	No	
Peng ²²⁸	2017	Pain Physician	No	No	No	

Feng ²²⁹	2016	Pharmazie	No	No	No	
Xu ²³⁰	2016	Pharmazie	No	No	No	
Palmeirim ²³¹	2018	PLOS Neglected Tropical Diseases	No	No	No	
Furukawa ²³²	2018	Psychotherapy and Psychosomatics	No	No	No	
Liu ²³³	2018	Renal Failure	No	No	No	
Miravittles ²³⁴	2017	Respiratory Research	Full	No	No	F
Wang ²³⁵	2017	Respiratory Research	No	No	No	
Kawalec ²³⁶	2018	Rheumatology International	No	No	No	
Malhotra ²³⁷	2018	Stroke	No	No	No	
Zhang ²³⁸	2018	Surgical Laparoscopy Endoscopy & Percutaneous Techniques	No	No	No	
Yamashita ²³⁹	2018	Thrombosis Research	No	No	Partial	E
Zhang ²⁴⁰	2018	Vaccine	No	No	No	
Other (n = 10)						
Medical Science						
Chen ²⁴¹	2018	Monitor	No	No	No	
Arteagoitia ²⁴²	2018	PLOS ONE	No	No	No	
Feng ²⁴³	2018	PLOS ONE	No	No	No	
Kawakami ²⁴⁴	2018	PLOS ONE	No	No	No	
Li ²⁴⁵	2018	PLOS ONE	No	No	No	
Lin ²⁴⁶	2017	PLOS ONE	No	No	No	
Ling ²⁴⁷	2018	PLOS ONE	No	No	No	
Rohner ²⁴⁸	2017	PLOS ONE	No	No	No	
Sethi ²⁴⁹	2018	PLOS ONE	Partial	No	No	F
Wolf ²⁵⁰	2018	PLOS ONE	No	No	No	

^aFunding sources categorized as government funded, industry funded, or mixed for most trials. Specific details about funding were reported for 2 trials and details on author ties and employment were reported for a single trial; ^bAuthors reported extracting funding sources from included RCTs but funding sources are only reported for a single study; ^cReported funding sources for all included studies except for one; ^dReported author financial ties for all included studies except for 2; ^eNon-industry author employment reported for some included RCTs; ^fFunding sources and author ties reported for all included RCTs except one that was a conference abstract; ^gFunding sources only reported for a single RCT; ^hAuthors reported whether or not included RCTs had declared COI (yes, no) and, if yes, indicated the page of the original study the declaration could be found on. This was coded as partially reporting because the nature of these COI was not reported within the meta-analysis publication itself and it was unclear whether these were financial ties and whether they were with industry; ⁱNon-industry author financial ties reported for some included RCTs; ^jA single RCT was reported as 'industry sponsored' with no specifics about the sponsor; ^kAuthors coded studies as sponsored by industry or not, and any of author industry affiliation, industry funding, or data obtained from pharmaceutical company qualified an RCT as 'sponsored'; ^lAuthors report that 'some trials had a high risk of reporting bias because they were sponsored by pharmaceutical companies' but do not specify which or even how many trials; ^mAuthors reported that all included RCTs had authors with financial ties to industry but provided no further information; ⁿReported whether each included RCT was industry funded (yes or no) but provided no further information; ^oFor some analyses the authors reported how many included RCTs were non-commercially funded and present results including only non-commercially funded trials, but do not provide further information on which trials were commercially funded; ^pAuthors state 14 trials were industry-sponsored and reference figure 1 in the supplementary material where 14 studies were marked as high risk for other bias, but it is not explicitly specified what was considered as 'other bias'; ^qAuthors considered RCT funding sources within 'other bias'. In their risk of bias assessment but did not report any specific information; ^rAuthors report that most studies were funded by the pharmaceutical industry and refer readers to figure 2 (risk of bias figure), but the figure does not give any information about which RCTs; ^sIncluded RCTs were coded as having company funding (Yes/No).

References for eTable1 and eTable2

1. Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. *Cochrane Database of Syst Rev.* 2018;4.
2. Adams SP, Sekhon SS, Tsang M, Wright JM. Fluvastatin for lowering lipids. *Cochrane Database of Syst Rev.* 2018;3.
3. Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. *Cochrane Database of Syst Rev.* 2018;4.
4. Al-Shahi Salman, Law ZK, Bath PM, Steiner T, Sprigg N. Haemostatic therapies for acute spontaneous intracerebral haemorrhage. *Cochrane Database of Syst Rev.* 2018;4.
5. Alabed S, Latifeh Y, Mohammad HA, Bergman H. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. *Cochrane Database of Syst Rev.* 2018;4.
6. Allegretti AS, Israelsen M, Krag A, Jovani M, Goldin AH, Schulman AR, et al. Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. *Cochrane Database of Syst Rev.* 2017;6.
7. Arechabala MC, Catoni MI, Claro JC, Rojas NP, Rubio ME, Calvo MA, et al. Antimicrobial lock solutions for preventing catheter-related infections in haemodialysis. *Cochrane Database of Syst Rev.* 2018;4.
8. Baandrup L, Ebdrup BH, JØ R, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. *Cochrane Database of Syst Rev.* 2018;3.
9. Bala MM, Paszek E, Lesniak W, Wloch-Kopec D, Jasinska K, Undas A. Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. *Cochrane Database of Syst Rev.* 2018;7.
10. Barbato A, Avanzo BD, Parabiaghi A. Couple therapy for depression. *Cochrane Database of Syst Rev.* 2018;6.
11. Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. *Cochrane Database of Syst Rev.* 2018;1.
12. Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, et al. Antidepressants versus placebo for panic disorder in adults. *Cochrane Database of Syst Rev.* 2018;4.

13. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database of Syst Rev.* 2018;6.
14. Boyapati RK, Torres J, Palmela C, Parker CE, Silverberg OM, Upadhyaya SD, et al. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. *Cochrane Database of Syst Rev.* 2018;5.
15. Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. *Cochrane Database of Syst Rev.* 2018;5.
16. Bruins Slot KMH, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. *Cochrane Database of Syst Rev.* 2018;3.
17. Bryan EJ, Purcell MA, Kumar A. Zuclopenthixol dihydrochloride for schizophrenia. *Cochrane Database of Syst Rev.* 2017;11.
18. Bryant-Smith AC, Lethaby A, Farquhar C, Hickey M. Antifibrinolytics for heavy menstrual bleeding. *Cochrane Database of Syst Rev.* 2018;4.
19. Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, et al. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. *Cochrane Database of Syst Rev.* 2018;6.
20. Campschroer T, Zhu X, Vernooij RW, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. *Cochrane Database of Syst Rev.* 2018;4.
21. Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. *Cochrane Database of Syst Rev.* 2018;6.
22. Chiew AL, Gluud C, Brok J, Buckley NA. Interventions for paracetamol (acetaminophen) overdose. *Cochrane Database of Syst Rev.* 2018;2.
23. Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. *Cochrane Database of Syst Rev.* 2018;7.
24. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Pietrantonj CD. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Syst Rev.* 2018;2.
25. Demicheli V, Jefferson T, Pietrantonj CD, Ferroni E, Thorning S, Thomas RE, et al. Vaccines for preventing influenza in the elderly. *Cochrane Database of Syst Rev.* 2018;2.

26. Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. *Cochrane Database of Syst Rev.* 2018;2.
27. El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia. *Cochrane Database of Syst Rev.* 2018;1.
28. Engelen ET, Schutgens RE, Mauser-Bunschoten EP, Es RJv, Galen KPv. Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. *Cochrane Database of Syst Rev.* 2018;7.
29. Eshun-Wilson I, Siegfried N, Akena DH, Stein DJ, Obuku EA, Joska JA. Antidepressants for depression in adults with HIV infection. *Cochrane Database of Syst Rev.* 2018;1.
30. Essali A, Soares-Weiser K, Bergman H, Adams CE. Calcium channel blockers for antipsychotic-induced tardive dyskinesia. *Cochrane Database of Syst Rev.* 2018;3.
31. Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, et al. Antidepressants for insomnia in adults. *Cochrane Database of Syst Rev.* 2018;5.
32. Fanshawe TR, Halliwell W, Lindson N, Aveyard P, Livingstone-Banks J, Hartmann-Boyce J. Tobacco cessation interventions for young people. *Cochrane Database of Syst Rev.* 2017;11.
33. Franik S, Eltrop SM, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. *Cochrane Database of Syst Rev.* 2018;5.
34. González R, Pons-Duran C, Piqueras M, Aponte JJ, Kuile FOT, Menéndez C. Mefloquine for preventing malaria in pregnant women. *Cochrane Database of Syst Rev.* 2018;3.
35. Grabosch SM, Shariff OM, Helm CW. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia. *Cochrane Database of Syst Rev.* 2018;2.
36. Graves PM, Choi L, Gelband H, Garner P. Primaquine or other 8-aminoquinolines for reducing *Plasmodium falciparum* transmission. *Cochrane Database of Syst Rev.* 2018;2.
37. Haas DM, Morgan S, Contreras K, Enders S. Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections. *Cochrane Database of Syst Rev.* 2018;7.

38. Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosunico VE, Terrenato I, et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. *Cochrane Database of Syst Rev.* 2018;1.
39. Heras-Mosteiro J, Monge-Maillo B, Pinart M, Pereira PL, Reveiz L, Garcia-Carrasco E, et al. Interventions for Old World cutaneous leishmaniasis. *Cochrane Database of Syst Rev.* 2017;12.
40. Janmaat VT, Steyerberg EW, Gaast Avd, Mathijssen RH, Bruno MJ, Peppelenbosch MP, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. *Cochrane Database of Syst Rev.* 2017;11.
41. Jefferson T, Rivetti A, Pietrantonj CD, Demicheli V. Vaccines for preventing influenza in healthy children. *Cochrane Database of Syst Rev.* 2018;2.
42. Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database of Syst Rev.* 2017;11.
43. Kaempfen S, Neumann RP, Jost K, Schulzke SM. Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. *Cochrane Database of Syst Rev.* 2018;3.
44. Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Barba M, Yosunico VED, et al. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database of Syst Rev.* 2017;12.
45. Kahale LA, Tsolakian IG, Hakoum MB, Matar CF, Barba M, Yosunico VE, et al. Anticoagulation for people with cancer and central venous catheters. *Cochrane Database of Syst Rev.* 2018;6.
46. Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. *Cochrane Database of Syst Rev.* 2018;6.
47. Kapur N, Petsky HL, Bell S, Kolbe J, Chang AB. Inhaled corticosteroids for bronchiectasis. *Cochrane Database of Syst Rev.* 2018;5.
48. Kelly C, Chalmers JD, Crossingham I, Relph N, Felix LM, Evans DJ, et al. Macrolide antibiotics for bronchiectasis. *Cochrane Database of Syst Rev.* 2018;3.

49. Knightly R, Milan SJ, Hughes R, Knopp-Sihota JA, Rowe BH, Normansell R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. *Cochrane Database of Syst Rev.* 2017;11.
50. Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). *Cochrane Database of Syst Rev.* 2018;6.
51. Lawrie TA, Green JT, Beresford M, Wedlake L, Burden S, Davidson SE, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. *Cochrane Database of Syst Rev.* 2018;1.
52. Leathersich SJ, Vogel JP, Tran TS, Hofmeyr GJ. Acute tocolysis for uterine tachysystole or suspected fetal distress. *Cochrane Database of Syst Rev.* 2018;7.
53. Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. *Cochrane Database of Syst Rev.* 2017;11.
54. López-Briz E, Garcia VR, Cabello JB, Bort-Martí S, Sanchis RC, Burls A. Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults. *Cochrane Database of Syst Rev.* 2018;7.
55. Marchant JM, Petsky HL, Morris PS, Chang AB. Antibiotics for prolonged wet cough in children. *Cochrane Database of Syst Rev.* 2018;7.
56. Matar HE, Almerie MQ, Sampson SJ. Fluphenazine (oral) versus placebo for schizophrenia. *Cochrane Database of Syst Rev.* 2018;6.
57. Matar CF, Kahale LA, Hakoum MB, Tsolakian IG, Etxeandia-Ikobaltzeta I, Yosucio VE, et al. Anticoagulation for perioperative thromboprophylaxis in people with cancer. *Cochrane Database of Syst Rev.* 2018;7.
58. McNicol ED, Rowe E, Cooper TE. Ketorolac for postoperative pain in children. *Cochrane Database of Syst Rev.* 2018;7.
59. McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. *Cochrane Database of Syst Rev.* 2018;1.
60. Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. *Cochrane Database of Syst Rev.* 2017;12.
61. Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. *Cochrane Database of Syst Rev.* 2018;5.

62. Monk AB, Harrison JE, Worthington HV, Teague A. Pharmacological interventions for pain relief during orthodontic treatment. *Cochrane Database of Syst Rev.* 2017;11.
63. Montero N, Favà A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, et al. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. *Cochrane Database of Syst Rev.* 2018;5.
64. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. *Cochrane Database of Syst Rev.* 2018;3.
65. Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn's disease. *Cochrane Database of Syst Rev.* 2018;4.
66. Nevitt SJ, Sudell M, Weston J, Smith CT, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. *Cochrane Database of Syst Rev.* 2017;12.
67. Nevitt SJ, Smith CT, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. *Cochrane Database of Syst Rev.* 2018;6.
68. Norman G, Westby MJ, Rithalia AD, Stubbs N, Soares MO, Dumville JC. Dressings and topical agents for treating venous leg ulcers. *Cochrane Database of Syst Rev.* 2018;6.
69. Normansell R, Sayer B, Waterson S, Dennett EJ, Forno MD, Dunleavy A. Antibiotics for exacerbations of asthma. *Cochrane Database of Syst Rev.* 2018;6.
70. Novoa M, Baselga E, Beltran S, Giraldo L, Shahbaz A, Pardo-Hernandez H, et al. Interventions for infantile haemangiomas of the skin. *Cochrane Database of Syst Rev.* 2018;4.
71. Ohlsson A, Aher SM. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. *Cochrane Database of Syst Rev.* 2017;11.
72. Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). *Cochrane Database of Syst Rev.* 2018;1.
73. Ostinelli EG, Hussein M, Ahmed U, Rehman FU, Miramontes K, Adams CE. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). *Cochrane Database of Syst Rev.* 2018;4.

74. Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. *Cochrane Database of Syst Rev.* 2018;4.
75. Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn's disease. *Cochrane Database of Syst Rev.* 2018;4.
76. Pasquali S, Hadjinicolaou AV, Sileni VC, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. *Cochrane Database of Syst Rev.* 2018;2.
77. Pike KC, Akhbari M, Kneale D, Harris KM. Interventions for autumn exacerbations of asthma in children. *Cochrane Database of Syst Rev.* 2018;3.
78. Rirash F, Tingey PC, Harding SE, Maxwell LJ, Ghogomu ET, Wells GA, et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. *Cochrane Database of Syst Rev.* 2017;12.
79. Robertson L, Yeoh SE, Ramli A. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. *Cochrane Database of Syst Rev.* 2017;12.
80. Romero L, Huerfano C, Grillo-Ardila CF. Macrolides for treatment of *Haemophilus ducreyi* infection in sexually active adults. *Cochrane Database of Syst Rev.* 2017;12.
81. Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. *Cochrane Database of Syst Rev.* 2018;4.
82. Rüschen H, Aravinth K, Bunce C, Bokre D. Use of hyaluronidase as an adjunct to local anaesthetic eye blocks to reduce intraoperative pain in adults. *Cochrane Database of Syst Rev.* 2018;3.
83. Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL. Pharmacological interventions for apathy in Alzheimer's disease. *Cochrane Database of Syst Rev.* 2018;5.
84. Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. *Cochrane Database of Syst Rev.* 2018;1.
85. Schumann J, Henrich EC, Strobl H, Prondzinsky R, Weiche S, Thiele H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. *Cochrane Database of Syst Rev.* 2018;1.
86. Simancas-Racines D, Arevalo-Rodriguez I, Osorio D, Franco JV, Xu Y, Hidalgo R. Interventions for treating acute high altitude illness. *Cochrane Database of Syst Rev.* 2018;6.

87. Smith S, Edwards CT. Long-acting inhaled bronchodilators for cystic fibrosis. *Cochrane Database of Syst Rev.* 2017;12.
88. Smith LA, Burns E, Cuthbert A. Parenteral opioids for maternal pain management in labour. *Cochrane Database of Syst Rev.* 2018;6.
89. Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. *Cochrane Database of Syst Rev.* 2018;3.
90. Squizzato A, Bellesini M, Takeda A, Middeldorp S, Donadini MP. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. *Cochrane Database of Syst Rev.* 2017;12.
91. St George G, Morgan A, Meechan J, Moles DR, Needleman I, Ng YL, et al. Injectable local anaesthetic agents for dental anaesthesia. *Cochrane Database of Syst Rev.* 2018;7.
92. Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. *Cochrane Database of Syst Rev.* 2017;12.
93. Sturman N, Deckx L, Driel MLv. Methylphenidate for children and adolescents with autism spectrum disorder. *Cochrane Database of Syst Rev.* 2017;11.
94. Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. *Cochrane Database of Syst Rev.* 2018;3.
95. Temmingh HS, Williams T, Siegfried N, Stein DJ. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. *Cochrane Database of Syst Rev.* 2018;1.
96. Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I, et al. Treatment for HIV-associated cryptococcal meningitis. *Cochrane Database of Syst Rev.* 2018;7.
97. Toews I, George AT, Peter JV, Kirubakaran R, Fontes LES, Ezekiel JPB, et al. Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units. *Cochrane Database of Syst Rev.* 2018;6.
98. Venekamp RP, Mick P, Schilder AG, Nunez DA. Grommets (ventilation tubes) for recurrent acute otitis media in children. *Cochrane Database of Syst Rev.* 2018;5.
99. Vermeij JD, Westendorp WF, Dippel DW, Beek Dvd, Nederkoorn PJ. Antibiotic therapy for preventing infections in people with acute stroke. *Cochrane Database of Syst Rev.* 2018;1.

100. Vietto V, Franco JV, Saenz V, Cytryn D, Chas J, Ciapponi A. Prostanoids for critical limb ischaemia. *Cochrane Database of Syst Rev.* 2018;1.
101. Wall EC, Ajdukiewicz KM, Bergman H, Heyderman RS, Garner P. Osmotic therapies added to antibiotics for acute bacterial meningitis. *Cochrane Database of Syst Rev.* 2018;2.
102. Weibel S, Jeltng Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. *Cochrane Database of Syst Rev.* 2018;6.
103. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. *Cochrane Database of Syst Rev.* 2018;4.
104. Xiao Y, Luo M, Wang J, Luo H. Losigamone add-on therapy for focal epilepsy. *Cochrane Database of Syst Rev.* 2018;1.
105. Zhang X, Chuai Y, Nie W, Wang A, Dai G. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. *Cochrane Database of Syst Rev.* 2017;11.
106. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. *Cochrane Database of Syst Rev.* 2017;12.
107. Zonneveld TP, Richard E, Vergouwen MD, Nederkoorn PJ, Haan Rd, Roos YB, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. *Cochrane Database of Syst Rev.* 2018;7.
108. López - López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. *BMJ (Clinical research ed).* 2017;359.
109. Wang W, Chen W, Liu Y, Siemieniuk RAC, Li L, Martínez JPD, et al. Antibiotics for uncomplicated skin abscesses: systematic review and network meta-analysis. *BMJ Open.* 2018;8(2).
110. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment

- of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. 2018;391(10128)1357-66.
- 111.Chen M, Ji M, Si X. The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials. *Medicine*. 2018;97(31).
- 112.Ding W, Li Z, Wang C, Ruan G, Chen L, Tu C. The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis. *Medicine*. 2018;97(20).
- 113.Guo P, He Z, Wang Y, Gao F, Sun W, Guo W, et al. Efficacy and safety of oral tranexamic acid in total knee arthroplasty: A systematic review and meta-analysis. *Medicine*. 2018;97(18).
- 114.Han X, Zhang Y, Yin L, Zhang L, Wang Y, Zhang H, et al. Statin in the treatment of patients with myocardial infarction: A meta-analysis. *Medicine*. 2018;97(12).
- 115.Hu W, Tong J, Kuang X, Chen W, Liu Z. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis. *Medicine*. 2018;97(3).
- 116.Huang ST, Tian BS, Xiao O, Yang YJ, Zhou SY. Safety of antivascular endothelial growth factor administration in the ocular anterior segment in pterygium and neovascular glaucoma treatment: Systematic review and meta-analysis. *Medicine*. 2018;97(34).
- 117.Jiang DQ, Xu LC, Jiang LL, Li MX, Wang Y. Fasudil combined with methylcobalamin or lipoic acid can improve the nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis. *Medicine*. 2018;97(27).
- 118.Jiang Y, Sun X, Kong B, Jiang J. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials. *Medicine*. 2018;97(34).
- 119.Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. *Medicine*. 2018;97(33).
- 120.Liang L, Cai Y, Li A, Ma C. The efficiency of intravenous acetaminophen for pain control following total knee and hip arthroplasty: A systematic review and meta-analysis. *Medicine*. 2017;96(46).
- 121.Liu X, Li X, Zhang C, Sun M, Sun Z, Xu Y, et al. Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: A meta-analysis. *Medicine*. 2018;97(28).

122. Lor YC, Shih PC, Chen HH, Liu SJ, Chao HC, Hwang LC, et al. The application of lidocaine to alleviate the discomfort of nasogastric tube insertion: A systematic review and meta-analysis. *Medicine*. 2018;97(5).
123. Wang W, Yu J. Tranexamic acid reduces blood loss in intertrochanteric fractures: A meta-analysis from randomized controlled trials. *Medicine*. 2017;96(52).
124. Wang H, Liu A, Bo W, Feng X, Hu Y. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. *Medicine*. 2018;97(16).
125. Wang Z, Hu Z, Dai T. The comparison of propofol and midazolam for bronchoscopy: A meta-analysis of randomized controlled studies. *Medicine*. 2018;97(36).
126. Wei W, Luo Z. Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. *Medicine*. 2017;96(48).
127. Woo HL, Ji HR, Pak YK, Lee H, Heo SJ, Lee JM, et al. The efficacy and safety of acupuncture in women with primary dysmenorrhea: A systematic review and meta-analysis. *Medicine*. 2018;97(23).
128. Xia Y, Fang H, Xu J, Jia C, Tao G, Yu B. Clinical efficacy of xenon versus propofol: A systematic review and meta-analysis. *Medicine*. 2018;97(20).
129. Yang Q, Zhang Z, Xin W, Li A. Preoperative intravenous glucocorticoids can decrease acute pain and postoperative nausea and vomiting after total hip arthroplasty: A PRISMA-compliant meta-analysis. *Medicine*. 2017;96(47).
130. Ye F, Wu Y, Zhou C. Effect of intravenous ketamine for postoperative analgesia in patients undergoing laparoscopic cholecystectomy: A meta-analysis. *Medicine*. 2017;96(51).
131. Yu L, Cao L, Sun J, Li Z, Yao F, Zhou Y. Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis. *Medicine*. 2018;97(25).
132. Yuan C, Xu XH, Luo SW, Wang L, Sun M, Ni LH, et al. Which neoadjuvant chemotherapy regimen should be recommended for patients with advanced nasopharyngeal carcinoma?: A network meta-analysis. *Medicine*. 2018;97(34).
133. Zhang JJ, Liu X. Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. *Medicine*. 2018;97(13).

134. Zhang J, Cai WK, Zhang Z, Wang P, Lin XQ, Feng J, et al. Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis. *Medicine*. 2018;97(15).
135. Zhao JB, Li YL, Wang YM, Teng JL, Xia DY, Zhao JS, et al. Intravenous lidocaine infusion for pain control after laparoscopic cholecystectomy: A meta-analysis of randomized controlled trials. *Medicine*. 2018;97(5).
136. Zhao T, Shen Z, Sheng S. The efficacy and safety of nefopam for pain relief during laparoscopic cholecystectomy: A meta-analysis. *Medicine*. 2018;97(10).
137. Zhou G, Ma L, Jing J, Jiang H. A meta-analysis of dexamethasone for pain management in patients with total knee arthroplasty. *Medicine*. 2018;97(35).
138. Zhu XT, Chen L, Lin JH. Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis. *Medicine*. 2018;97(31).
139. Zhou J, Zhang Q, Wang Y, Gao P, Chen D. The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis. *Postgrad Med*. 2018;130(1):129-36.
140. Zhang Y, Tao LN, Qu XY, Niu JQ, Ding YH, Zhang SX. Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials. *Rev Assoc Med Bras*. 2018;64(3):253-63.
141. Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. *Acta Ophthalmol*. 2018;96(3):e277-84.
142. Tarantini G, Ueshima D, Amico GD, Masiero G, Musumeci G, Stone GW, et al. Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis. *Am Heart J*. 2018;195:78-85.
143. Wang Y, Wang J, Wang S. Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials. *Am J Cardiovasc Drugs*. 2018;18(4):271-82.

144. Aman A, Salim B, Munshi K, Raza SA, Khan FA. Effect on neonatal outcome of pharmacological interventions for attenuation of the maternal haemodynamic response to tracheal intubation: a systematic review. *Anaesth Intensive Care*. 2018;46(3):258-71.
145. Li GM, Zhao J, Li B, Zhang XF, Ma JX, Ma XL, et al. The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. *Autoimmun Rev*. 2018;17(3):215-25.
146. Wang B, He X, Gong Y, Cheng B. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery: An Update Meta-Analysis and Trial Sequential Analysis. *BioMed Res Int*. 2018;2018:1-10.
147. Veettil SK, Lim KG, Ching SM, Saokaew S, Phisalprapa P, Chaiyakunapruk N. Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. *BMC Cancer*. 2017;17(1):763.
148. Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d'Avila R, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. *BMC Cardiovasc Disord*. 2018;18(1):24.
149. Lyu Y, Cheng Y, Wang B, Xu Y, Du W. What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials. *BMC Gastroenterol*. 2018;18(1):106.
150. Xing Y, Chen L, Feng Y, Zhou Y, Zhai Y, Lu J. Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections. *BMC Infect Dis*. 2017;17(1):798..
151. Kuo LT, Hsu WH, Chi CC, Yoo JC. Tranexamic acid in total shoulder arthroplasty and reverse shoulder arthroplasty: a systematic review and meta-analysis. *BMC Musculoskelet Disord*. 2018;19(1):60.
152. Beez T, Steiger HJ, Etminan N. Pharmacological targeting of secondary brain damage following ischemic or hemorrhagic stroke, traumatic brain injury, and bacterial meningitis - a systematic review and meta-analysis. *BMC Neurol*. 2017;17(1):209.

153. Zeng W, Liu Z, Dai H, Yan M, Luo H, Ke M, et al. Anti-fibrotic, anti-VEGF or radiotherapy treatments as adjuvants for pterygium excision: a systematic review and network meta-analysis. *BMC Ophthalmol.* 2017;17(1):211.
154. Bundhun PK, Shi JX, Huang F. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials. *BMC Pharmacol Toxicol.* 2017;18(1):80.
155. Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. *BMC Psychiatry.* 2017;17(1):373.
156. Zhang HL, Tan M, Qiu AM, Tao Z, Wang CH. Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis. *BMC pulmonary medicine.* 2017;17(1):196.
157. Zhang ZQ, Zhong Y, Huang XM, Du LZ. Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis. *BMC Pulm Med.* 2017;17(1):207.
158. Ramos-Esquivel A, Hernández-Steller H, Savard MF, Landaverde DU. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. *Breast Cancer.* 2018;25(4):479-88.
159. Zeng C, Wei J, Persson MSM, Sarmanova A, Doherty M, Xie D, et al. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. *Br J Sports Med.* 2018;52(10):642-50.
160. Shui L, Wu YS, Lin H, Shui P, Sun Q, Chen X. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis. *Cell Physiol Biochem.* 2018;48(5):1870-81.
161. Rodrigo C, Weeratunga P, Fernando SD, Rajapakse S. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies. *Clin Microbiol Infect.* 2018;24(6):591-8.

162. Wang S, He Q, Shuai Z. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. *Clin Rheumatol*. 2018;37(2):439-50.
163. Hong Y, Mansour S, Alotaibi G, Wu C, McMurtry MS. Effect of anticoagulants on admission rates and length of hospital stay for acute venous thromboembolism: A systematic review of randomized control trials. *Crit Rev Oncol Hematol*. 2018;125:12-18.
164. de Carvalho LSFd, Campos AM, Sposito AC. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. *Diabetes Care*. 2018;41(2):364-7.
165. Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. *Dig Dis Sci*. 2018;63(5):1250-60.
166. Liu J, Wang LN. The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis. *Drug Deliv*. 2018;25(1):43-8.
167. Liu LY, Liu Y, Wu MY, Sun YY, Ma FZ. Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis. *Drug Des Devel Ther*. 2018;12:437.
168. Sun S, Wang J, Bao N, Chen Y, Wang J. Comparison of dexmedetomidine and fentanyl as local anesthetic adjuvants in spinal anesthesia: a systematic review and meta-analysis of randomized controlled trials. *Drug Des Devel Ther*. 2017;11:3413.
169. Paraschakis A, Katsanos AH. Antidepressants for Depression Associated with Traumatic Brain Injury: A Meta-analytical Study of Randomised Controlled Trials. *East Asian Arch Psychiatry*. 2017;27(4):142.
170. D'Souza RS, Mercogliano C, Ojukwu E, Souza SD, Singles A, Modi J, et al. Effects of prophylactic anticholinergic medications to decrease extrapyramidal side effects in patients taking acute antiemetic drugs: a systematic review and meta-analysis. *Emerg Med J*. 2018;35(5):325-31.
171. Mei L, Hou Q, Fang F, Wang H. The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis. *Eur J Gynaecol Oncol*. 2016;37(4):455-60.

172. Verberkt CA, Everdingen MHJvdB-v, Schols J, Datla S, Dirksen CD, Johnson MJ, et al. Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. *Eur Respir J*. 2017;50(5):1701153.
173. Sridharan K, Sivaramakrishnan G, Gnanaraj J. Pharmacological interventions for stress ulcer prophylaxis in critically ill patients: a mixed treatment comparison network meta-analysis and a recursive cumulative meta-analysis. *Expert Opin Pharmacother*. 2018;19(2):151-8.
174. Habibi MR, Habibi V, Habibi A, Soleimani A. Lidocaine dose-response effect on postoperative cognitive deficit: meta-analysis and meta-regression. *Expert Rev Clin Pharmacol*. 2018;11(4):361-71.
175. Li Y, Liu H, Peng W, Song Z. Nicorandil improves clinical outcomes in patients with stable angina pectoris requiring PCI: a systematic review and meta-analysis of 14 randomized trials. *Expert Rev Clin Pharmacol*. 2018;11(9):855-65.
176. Sangroongruangsri S, Ratanapakorn T, Wu O, Anothaisintawee T, Chaikledkaew U. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. *Expert Rev Clin Pharmacol*. 2018;11(9):903-16.
177. Hickey BA, Watson U, Cleves A, Alikhan R, Pugh N, Nokes L, et al. Does thromboprophylaxis reduce symptomatic venous thromboembolism in patients with below knee cast treatment for foot and ankle trauma? A systematic review and meta-analysis. *Foot Ankle Surg*. 2018;24(1):19-27.
178. Zhao TT, Xu H, Xu HM, Wang ZN, Xu YY, Song YX, et al. The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials. *Gastric Cancer*. 2018;21(3):361-71.
179. Khara R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, et al. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. *Gastroenterology*. 2018;154(5):1309-19.
180. Li J, Li S, Yu H, Wang J, Xu C, Lu X. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis. *Gynecol Oncol*. 2018;148(2):247-53.

181. Zhuge L, Wang Y, Wu S, Zhao RL, Li Z, Xie Y. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. *Helicobacter*. 2018;23(2):e12468.
182. Kim MK, Myung SK, Tran BT, Park B. Statins and risk of cancer: A meta-analysis of randomized, double-blind, placebo-controlled trials. *Indian J Cancer*. 54(2):470.
183. Garg R, Mohan BP, Krishnamoorthi R, Rustagi T. Pre-endoscopic retrograde cholangiopancreatography (ERCP) administration of rectal indomethacin in unselected patients to reduce post-ERCP pancreatitis: A systematic review and meta-analysis. *Indian J Gastroenterol*. 2018;37(2):120-6.
184. Rosanova MT, Bes D, Aguilar PS, Sberna N, Lede R. Efficacy and safety of voriconazole in immunocompromised patients: systematic review and meta-analysis. *Infect Dis (Lond)*. 2018;50(7):489-94.
185. Yu J, Lu H, Zhou J, Xie Z, Wen C, Xu Z. Oral prednisolone versus non-steroidal anti-inflammatory drugs in the treatment of acute gout: a meta-analysis of randomized controlled trials. *Inflammopharmacology*. 2018;26(3):717-23.
186. Kakkos SK, Nicolaidis AN. Efficacy of micronized purified flavonoid fraction (Daflon) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. *Int Angiol*. 2018;37(2).
187. Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. *Intimmunopharmacol*. 2018;54:303-10.
188. Yin J, Xu B, Zeng X, Shen K. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. *Int immunopharmacol*. 2018;54:198-209.
189. Zhu J, Zhao W, Liang D, Li G, Qiu K, Wu J, et al. Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial. *Int J Clin Oncol*. 2018;23(2):389-99.
190. Liu H, Xu X. Influence of adjunctive lacosamide in patients with seizures: a systematic review and meta-analysis. *Int J Neurosci*. 2018;128(7):670-6.

191. Cocolini F, Nardi M, Montori G, Ceresoli M, Celotti A, Cascinu S, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. *Int J Surgery*. 2018;51:120-7.
192. Fan Z, Ma J, Kuang M, Zhang L, Han B, Yang B, et al. The efficacy of dexamethasone reducing postoperative pain and emesis after total knee arthroplasty: A systematic review and meta-analysis. *Int J Surgery*. 2018;52:149-55.
193. Li J, Wang G, Xu W, Ding M, Yu W. Efficacy of intravenous lidocaine on pain relief in patients undergoing laparoscopic cholecystectomy: A meta-analysis from randomized controlled trials. *Int J Surgery*. 2018;50:137-45.
194. Li S, Sheng G, Teng Y, Sun M. Systematic review of anaesthetic medication for ERCP based on a network meta-analysis. *Int J Surgery*. 2018;51:56-62.
195. Liu Q, Geng P, Shi L, Wang Q, Wang P. Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis. *Int J Surgery*. 2018;54:105-12.
196. Ran J, Yang X, Ren Z, Wang J, Dong H. Comparison of intra-articular hyaluronic acid and methylprednisolone for pain management in knee osteoarthritis: A meta-analysis of randomized controlled trials. *Int J Surgery*. 2018;53:103-10.
197. Zhao M, Xiang P, Jiang H. TransArterial ChemoEmbolicization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: A meta-analysis. *Int J Surgery*. 2018;53:151-8.
198. Zhu J, Xie H, Zhang L, Chang L, Chen P. Efficiency and safety of ketamine for pain relief after laparoscopic cholecystectomy: A meta-analysis from randomized controlled trials. *Int J Surgery*. 2018;49:1-9.
199. Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. *J Affect Disord*. 2018;228:1-12.
200. Hickman LC, Llarena NC, Valentine LN, Liu X, Falcone T. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists. *J Assist Reprod Genet*. 2018;35(4):571-81.

201. Luo W, Wang Z, Tian P, Li W. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. *J Cancer Res Clin Oncol*. 2018;144(10):1851-9.
202. Wang Y, Zhang H, Shen W, He P, Zhou Z. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials. *J Cancer Res Clin Oncol*. 2018;144(9):1751-68.
203. Wang DD, Ma TT, Zhu HD, Peng CB. Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials. *J Cancer Res Ther*. 2018;14(8):14.
204. Aboul-Hassan SS, Stankowski T, Marczak J, Peksa M, Nawotka M, Stanislawski R, et al. The use of preoperative aspirin in cardiac surgery: A systematic review and meta-analysis. *J Card Surg*. 2017;32(12):758-74.
205. Wang Y, Zhu S, R DU, Zhou J, Chen Y, Zhang Q. Statin initiation and renal outcomes following isolated coronary artery bypass grafting: a meta-analysis. *J Card Surg*. 2018;59(2):282-90.
206. Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, et al. Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. *J Clin Endocrinol Metab*. 2018;103(4):1258-64.
207. Cui JY, Zhou RR, Han S, Wang TS, Wang LQ, Xie XH. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis. *J Clin Pharm Ther*. 2018;43(4):556-70.
208. Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Møller AH. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. *J Dermatolog Treat*. 2018;29(6):557-68.
209. Markey GC, Salter N, Ryan J. Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation. *J Emerg Med*. 2018;54(3):320-7.
210. Szabó IL, Mátics R, Hegyi P, Garami A, Illés A, Sarlós P, et al. PPIs Prevent Aspirin-Induced Gastrointestinal Bleeding Better than H2RAs. A Systematic Review and Meta-analysis. *J Gastrointest Liver Dis: JGLD*. 2017;26(4):395-402.

211. Su Q, Zhang XC, Zhang CG, Hou YL, Yao YX, Cao BW. Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. *J Immunol Res*. 2018;2018:1-9.
212. Chen C, Zhou X, Zhu M, Chen S, Chen J, Cai H, et al. Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials. *J Interv Card Electrophysiol*. 2018;52(1):9-18.
213. Chen X, Mou X, He Z, Zhu Y. The effect of midazolam on pain control after knee arthroscopy: a systematic review and meta-analysis. *J Orthop Surg Res*. 2017;12(1):179.
214. Li YJ, Xu BS, Bai SP, Guo XJ, Yan XY. The efficacy of intravenous aminocaproic acid in primary total hip and knee arthroplasty: a meta-analysis. *J Orthop Surg Res*. 2018;13(1).
215. Luo W, Sun RX, Jiang H, Ma XL. The efficacy and safety of topical administration of tranexamic acid in spine surgery: a meta-analysis. *J Orthop Surg Res*. 2018;13(1):96.
216. Ma R, Chen GH, Zhao LJ, Zhai XC. Efficacy of naproxen prophylaxis for the prevention of heterotopic ossification after hip surgery: a meta-analysis. *J Orthop Surg Res*. 2018;13(1):48.
217. He H, Wang W, Lyu J, Zheng J, Guo L, An X, et al. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. *J Psychiatr Res*. 2018;96:247-59.
218. Wang KL, Chiu CC, Giugliano RP, Tan DS, Lin CY, Lai EY, et al. Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. *J Stroke Cerebrovasc Dis : the official journal of National Stroke Association*. 2018;27(4):857-64.
219. Dhana A, Yen H, Okhovat JP, Cho E, Keum N, Khumalo NP. Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta-analysis of randomized controlled trials. *J Am Acad Dermatol*. 2018;78(1):194-98.
220. Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, et al. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials. *J Am Heart Assoc*. 2017;6(12):e006910.

221. Kuo CM, Tung TH, Wang SH, Chi CC. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. *J Eur Acad of Dermatol Venereol*. 2018;32(3):355-62.
222. Liu W, Qian X, Ji W, Lu Y, Wei G, Wang Y. Effects and safety of Sinomenine in treatment of rheumatoid arthritis contrast to methotrexate: a systematic review and Meta-analysis. *J Tradit Chin Med*. 2016;36(5):564-77.
223. Zheng Y, Gu Q, Chen HW, Peng HM, Jia DY, Zhou Y, et al. Efficacy of amiodarone and lidocaine for preventing ventricular fibrillation after aortic cross-clamp release in open heart surgery: a meta-analysis of randomized controlled trials. *J Zhejiang Univ Sci B*. 18(12):1113-22.
224. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respir Med*. 2018;6(4):265-75.
225. Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. *Neurol Sci*. 2018;39(4):629-40.
226. Chen HJ, Lin C, Lee CH, Chen YH. Efficacy and Safety of Bevacizumab Combined with Mitomycin C or 5-Fluorouracil in Primary Trabeculectomy: A Meta-Analysis of Randomized Clinical Trials. *Ophthalmic Res*. 2018;59(3):155-63.
227. Han C, Kuang MJ, Ma JX, Ma XL. The Efficacy of Preoperative Gabapentin in Spinal Surgery: A Meta-Analysis of Randomized Controlled Trials. *Pain Physician*. 2017;20(7):649-61.
228. Peng K, Zhang J, Meng XW, Liu HY, Ji FH. Optimization of Postoperative Intravenous Patient-Controlled Analgesia with Opioid-Dexmedetomidine Combinations: An Updated Meta-Analysis with Trial Sequential Analysis of Randomized Controlled Trials. *Pain Physician*. 2017;20(7):569-96.
229. Feng M, Ding Q, Zhong C, Li J, Wang Q, Yuan Z, et al. Adjunctive therapy with V-5 Immunitor (V5) for the treatment of tuberculosis patients: a meta-analysis. *Pharmazie*. 2016;71(9):499-503.
230. Xu L, Zhang F, Du S, Yu Q, Chen L, Long LH, et al. Inhaled antibiotics in non-cystic fibrosis bronchiectasis: A meta-analysis. *Pharmazie*. 2016;71(9):491-8.

231. Palmeirim MS, Hürlimann E, Knopp S, Speich B, Belizario V, Joseph SA, et al. Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: A systematic review, meta-analysis and individual patient data analysis. *PLoS Negl Trop Dis*. 2018;12(4):e0006458.
232. Furukawa TA, Efthimiou O, Weitz ES, Cipriani A, Keller MB, Kocsis JH, et al. Cognitive-Behavioral Analysis System of Psychotherapy, Drug, or Their Combination for Persistent Depressive Disorder: Personalizing the Treatment Choice Using Individual Participant Data Network Metaregression. *Psychother Psychosom*. 2018;87(3):140-53.
233. Liu X, Zhai T, Ma R, Luo C, Wang H, Liu L. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. *Ren Fail*. 2018;40(1):289-97.
234. Miravittles M, Urrutia G, Mathioudakis AG, Ancochea J. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis. *Respir Res*. 2017;18(1):196.
235. Wang G, Zhang X, Zhang HP, Wang L, Kang Y, Barnes PJ, et al. Corticosteroid plus β 2-agonist in a single inhaler as reliever therapy in intermittent and mild asthma: a proof-of-concept systematic review and meta-analysis. *Respir Res*. 2017;18(1):203.
236. Kawalec P, Holko P, Mofáko P, Pilc A. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. *Rheumatol Int*. 2018;38(2):189-201.
237. Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis. *Stroke*. 2018;49(2):312-8.
238. Zhang R, Lu Q, Wu Y. The Comparison of Midazolam and Propofol in Gastrointestinal Endoscopy: A Systematic Review and Meta-analysis. *Surg Laparosc Endosc Percutan Tech*. 2018;28(3):153-8.
239. Yamashita Y, Morimoto T, Toyota T, Shiomi H, Makiyama T, Ono K, et al. Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: A systemic review and meta-analysis. *Thromb Res*. 2018;166:37-42.

240. Zhang W, Sun H, Atiquzzaman M, Sou J, Anis AH, Cooper C. Influenza vaccination for HIV-positive people: Systematic review and network meta-analysis. *Vaccine*. 2018;36(28):4077-86.
241. Chen H, Shen FE, Tan XD, Jiang WB, Gu YH. Efficacy and Safety of Acupuncture for Essential Hypertension: A Meta-Analysis. *Med Sci Monit*. 2018;24:2946.
242. Arteagoitia I, Andrés CR, Ramos E. Does chlorhexidine reduce bacteremia following tooth extraction? A systematic review and meta-analysis. *PloS one*. 2018;13(4):e0195592.
243. Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. *PloS one*. 2018;13(1).
244. Kawakami H, Mihara T, Nakamura N, Ka K, Goto T. Effect of magnesium added to local anesthetics for caudal anesthesia on postoperative pain in pediatric surgical patients: A systematic review and meta-analysis with Trial Sequential Analysis. *PloS one*. 2018;13(1):e0190798.
245. Li X, Zhu L, Zhou C, Liu J, Du H, Wang C, et al. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis. *PloS one*. 2018;13(3):e0194501.
246. Lin YC, Lin JW, Wu MS, Chen KC, Peng CC, Kang YN. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. *PloS one*. 2017;12(12):e0188975.
247. Ling X, Zhou H, Ni Y, Wu C, Zhang C, Zhu Z. Does dexmedetomidine have an antiarrhythmic effect on cardiac patients? A meta-analysis of randomized controlled trials. *PloS one*. 2018;13(3):e0193303.
248. Rohner E, Grabik M, Tonia T, Jüni P, Pöyry F, Pignatti F, et al. Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients. *PloS one*. 2017;12(12):e0189309.
249. Sethi NJ, Nielsen EE, Safi S, Feinberg J, Gluud C, Jakobsen JC. Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. *PloS one*. 2018;13(3):e0193924.

250. Wolf S, Hoffmann VS, Habicht A, Kauke T, Bucher J, Schoenberg M, et al. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. *PloS one*. 2018;13(4):e0194975.